Development of Polymeric Carriers for the Treatment of Acute Kidney Injury by Chen, Yi
University of Nebraska Medical Center 
DigitalCommons@UNMC 
Theses & Dissertations Graduate Studies 
Fall 8-24-2018 
Development of Polymeric Carriers for the Treatment of Acute 
Kidney Injury 
Yi Chen 
University of Nebraska Medical Center 
Follow this and additional works at: https://digitalcommons.unmc.edu/etd 
 Part of the Chemicals and Drugs Commons 
Recommended Citation 
Chen, Yi, "Development of Polymeric Carriers for the Treatment of Acute Kidney Injury" (2018). Theses & 
Dissertations. 291. 
https://digitalcommons.unmc.edu/etd/291 
This Dissertation is brought to you for free and open access by the Graduate Studies at DigitalCommons@UNMC. It 
has been accepted for inclusion in Theses & Dissertations by an authorized administrator of 
DigitalCommons@UNMC. For more information, please contact digitalcommons@unmc.edu. 
	Development of Polymeric Carriers for the Treatment of 
Acute Kidney Injury 
 
by 
Yi Chen 
A DISSERTATION 
Presented to the Faculty of 
the University of Nebraska Graduate College 
in Partial Fulfillment of the Requirements 
for the Degree of Doctor of Philosophy 
 
 
Pharmaceutical Sciences 
Graduate Program 
 
 
Under the Supervision of Professor David Oupický 
 
 
University of Nebraska Medical Center 
Omaha, Nebraska 
 
August, 2018 
 
Supervisory Committee: 
 
                      David Oupický, Ph.D.                              Aaron Mohs, Ph.D.                           
                      Babu Padanilam, Ph.D.                           Yuxiang Dong, Ph.D.  
 
	Acknowledgments 
I would like to take this opportunity to thank for my advisor, Prof. David Oupický 
for his continued support during the five years of my PhD study. It would not have been 
possible without his kind support and help from him. His advice on research as well as 
on my career have been priceless. I feel so lucky and proud to be his student. 
I would also like to appreciate the insights and support that I received from my 
committee members, Prof. Aaron Mohs, Babu Padanilam and Yuxiang Dong. Their 
continuous guidance and valuable suggestions during my research at UNMC have 
motivated me to widen my research from various perspectives. 
My thanks also go to Dr. Yuan Ying for the help with renal ischemia-reperfusion 
animal model and Dr. Heeseong Jang for the help with renal tubular injury score and a 
kind provision of mouse renal cell line. I especially thank all our former and current group 
members, for their help, suggestions and encouragement throughout the years. I would 
like to thank Dr. Jing Li, who always give me continuous encouragements, talented 
suggestions, countless help and guidance. I would also like to thank Dr. Yan Wang who 
taught me all the regular experiments in vitro and in vivo when I just came to this lab. I 
would thank Fei Yu for helping me with the chemistry and Ying Xie with his help for flow 
cytometry. Special thanks go to my other lab mates for their support in and out of lab over 
these years. 
Lastly, I would like to thank my parents, my husband, my daughter and my 
friends for their wonderful company, unlimited spiritual support, love and 
encouragement throughout my study and my life in general. 
	Abstract: 
Development of Polymeric Carriers for the Treatment of Acute Kidney Injury 
Yi Chen, Ph.D. 
University of Nebraska Medical Center, 2018 
Supervisor: David Oupický, Ph.D. 
          Acute kidney injury (AKI) is a major kidney disease associated with high mortality 
and morbidity. Long-term AKI may lead to chronic kidney disease and end-stage renal 
disease. Several clinical trials failed due to lack of efficacy and undesired side effects. 
Studies showed that macromolecular delivery systems would be a promising method to 
target kidney, however, little is known about how physicochemical properties affects the 
polymers deposition in ischemia-reperfusion (I/R) AKI.  
          Gene therapy has been well studied as a promising therapeutic agent for several 
diseases, including cancer and AKI. Although small interfering RNA (siRNA) has been 
commonly used to treat AKI through hydrodynamic injection, this method has some 
disadvantages.  
          The expression of CXCR4 increases in response to AKI. Emerging evidence shows 
that CXCR4/SDF-1 axis is implicated in regulating trafficking and invasion of 
inflammatory cells in the injured kidneys. The inhibition of the axis appears to exert 
beneficial therapeutic effect in AKI.  
          First, to understand how physicochemical properties affects renal accumulation in 
AKI, we synthesized a panel of 9 fluorescently labeled polymers with a range of size and 
	different net charge. By testing biodistribution in unilateral I/R animal model, we found 
negatively charged pMAA-5 and neutral pHPMA-36 had greatest potential for 
accumulating in I/R kidneys as compared with sham-operated kidneys. The polymers 
passed through glomerulus and sustained in proximal tubular cells for up to 24 hours 
after injection. We also confirmed the consistency of bilateral and unilateral I/R animal 
model by confirming biodistribution of pAPMA-30 and pHPMA-16 in bilateral I/R animal 
model. This study demonstrated for the first time that polymers with specific physical 
characteristics exhibit promising enhanced ability to accumulate in AKI kidney. 
          Second, to explore the potential of CXCR4/SDF-1 axis in the treatment of AKI, we 
formulated polyplexes with our previously synthesized polymeric CXCR4 antaganist 
(PCX). Biodistribution study indicated that the majority of injected polyplexes can 
accumulated in injured renal rubule cells. Transfection effect of the polyplexes in 
unilateral I/R injury mouse model showed a better silencing effect complared with 
hydrodynamic injection, which providing a novel dual-functional pharmacological 
method for treatment of AKI. 
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Chapter 1. Introduction 
1. Renal Anatomy and Selective Permeability 
1.1. Renal Anatomy 
          Kidneys are organs that are highly vascularized and function as osmoregulators by 
selective filtration, resorption, secretion and excretion. As shown in Scheme 1A, one 
kidney of healthy adult human contains about one million nephrons which are the units 
of kidney [1]. One nephron is composed of a renal corpuscle and a hairpin-shaped tubule. 
Renal corpuscle consists of a cluster of capillaries named glomerulus and Bowman’s 
capsule. Proximal tubule, loop of Henle, distal tubule and collecting duct make up to the 
whole tubule system. The glomerulus prevents large molecules, blood cells and most 
proteins from elimination while filtering fluid and waste products into tubules in which 
several minerals are reabsorbed back to bloodstream and wastes are removed into urine.  
1.2. Selective Permeability 
          The glomerular filtration barrier, located within the glomerulus of the nephron, is 
made up of three different parts, including glomerular endothelial fenestrations [2], 
glomerular basement membrane (GBM) [3], and podocytes [4] (Scheme 1B). The 
glomerular endothelial fenestrations have the pore size of around 100 nm in diameter [5]. 
The GBM is a 300-nm-thick connective tissue membrane with presence of heparin sulfate 
[6] and negatively charged proteoglycans. Its average pore size is 3 nm [7]. The GBM 
serves as a size and charge-selective filtration barrier. The podocyte slit pores attached 
over the surface of the GBM towards to the urinary space has average width of 15 nm [8]. 
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Taken together, the glomerular filtration barrier functions as an effective size cutoff for 
the molecules or particles with size less than 10 nm to enter urinary space from the blood 
circulation [9]. In other words, structural features of the glomerular barrier can be a 
criterion for nanoparticles design to target kidney in diverse renal diseases.  
        The synthesis and application of nanoparticles have been attracted much attention in 
biopharmaceutical areas, such as drug delivery [10, 11], therapeutics [12] and diagnostic 
imaging [13, 14]. Effective therapeutic outcomes require specific features of nanoparticles 
to overcome biological barriers, accumulate in target tissue and escape from rapid 
clearance [15, 16]. Therefore, it is of great importance to understand the effect of different 
properties of nanoparticles on biological distribution [17].   
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Scheme 1. Renal anatomy. A) Nephron of kidney which consists of renal corpuscle and 
hairpin-shaped tubules. B) Detailed structure of glomerulus (Adapted from [18]). 
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1.2.1 Nanoparticle Size 
          The effect of nanoparticle size on in vivo biodistribution has been widely 
investigated by several studies. Nanoparticles smaller than 10 nm can be subject to rapid 
clearance by kidney and be excreted from the body.  Over 50% of injected dose of 
nanoparticles can be excreted via renal clearance 4 h after administration if hydrodynamic 
diameter is below 5.5 nm [9, 15]. Larger nanoparticles over 100 nm are taken up and 
degraded by spleen and liver [19]. Nanoparticles with size between these two ranges (10-
100 nm) typically have longer circulation time in blood and will not be filtered by kidney 
into the urine unless they are degraded into smaller particles [20, 21]. Given that some 
studies have shown inorganic nanoparticles with the size ranging from 12-16 nm passed 
through this filtration threshold [22], this may not be a strict rule for renal clearance of all 
types of nanoparticles and each study should be case-by-case due to distinct chemical 
composition and size-distribution profile of each type of nanoparticles.         
1.2.2 Nanoparticle Charge 
          The surface charge of nanoparticles plays an important role in determining 
nonspecific cellular internalization and protein absorption during circulation which are 
the concerns when it comes to systemic delivery. Among nanoparticles with positive, 
negative and neutral charge, highly positively charged nanoparticles have the highest rate 
of cell uptake. It has been also well accepted that nanoparticles with highly positive charge 
are more subject to protein binding and uptake by phagocytes, leading to high nonspecific 
internalization rate and rapid clearance by reticuloendothelial system (RES) [23, 24]. 
Compared to neutral nanoparticles, nanoparticles with negative charge still have more 
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non-specific cellular uptake [25]. Yamamoto et.al. demonstrated negatively charged 
micelles exhibited less uptake in liver and spleen than neutral micelles due to synergic 
steric and electrostatic repulsion [26].  
          Given the negative charge of the GBM, charge selectivity is also an important 
criterion of nanoparticles design for kidney filtration or targeting different renal cells. 
Gold nanoparticles with positive charge accumulate in glomeruli 24 h after administration, 
whereas neutral and negatively charged gold nanoparticles do not. Neutral gold 
nanoparticles accumulate extensively in the arteries and negative gold nanoparticles are 
distributed in the kidney homogeneously, indicating the influence of surface charge on 
gold nanoparticles filtration by kidney [27].  
1.2.3 Nanoparticle Shape 
        The structural features of nanoparticles are also responsible for dramatically different 
renal clearance profile which is important aspect for design of targeted drug delivery 
systems. Although it is well recognized that nanoparticles less than the 10-nm cutoff of 
the kidney filtration barrier can pass through GBM, nanoparticles larger than 10 nm but 
with high aspect ratios have been demonstrated to cross GBM paradoxically. Several 
studies have demonstrated that single-walled carbon nanotubes with average diameter 
less than 10 nm and average size 100 to 500 nm had rapid and effective renal clearance  
with half-life of a few hours [28-31]. Based on the multimodal imaging methods, including 
simultaneous dynamic positron emission tomography, near-infrared fluorescence 
imaging and microscopy, Ruggiero and colleagues demonstrated that hydrostatic forces 
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in glomerulus make the long axis of carbon nanotubes in a perpendicular orientation to 
GBM, thereby their short axis is oriented horizontally to GBM [30]. Another group showed 
the consistent result by transmission electron microscopy imaging [31].  
2. Acute Kidney Injury 
          Acute kidney injury (AKI) can be characterized by an abrupt decline in the 
glomerular filtration rate over a period of minutes to days that inhibits balance of 
electrolyte, fluid and acid/base [32]. Clinically, AKI is mainly triggered by toxic responses 
to medications, ischemia which results from a reduction of blood flow in kidney by 
decreased cardiac output (cardiac surgery), and sepsis [33-35]. It is a complex disorder 
and impacts about 13.3 million people annually [36]. There are about 1.7 million people 
who die annually from AKI in the world [37-39]. The long-term outcomes of AKI for 
patients may further develop into chronic kidney disease and end-stage renal disease, 
which can lead to poor life quality and high long-term costs [40, 41]. Although people 
have achieved substantial progress in treating AKI clinically by intensive care medicine 
and dialysis, the prognosis has not significantly been improved and the mortality 
remained 30-50% over the last decades [42]. Therefore, AKI is a major global health 
problem that is associated with high morbidity and high mortality.  
          In the past, there has been no uniform accepted definition for AKI, which made it 
difficult to clarify the incidence of AKI and hindered early recognition and management 
of AKI. As lots of efforts of basic and clinical researchers have been focused on AKI over 
the last decades, there is a great need to define a uniform criteria for AKI. The Kidney 
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Disease: Improving Global Outcomes (KDIGO) group has recognized these limitations 
and proposed a universal definition and staging system of AKI for practice, research and 
public health [43], which describes that serum creatinine and urine output are the 
standard diagnostic biomarkers for measuring kidney function. As is shown in Table 1, 
AKI occurs within a broad spectrum ranging from the small changes in blood chemistry 
of patients (mild injury) to renal failure that needs renal replacement therapy (most severe 
impairment).  
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Table 1. KDIGO staging system for AKI (Adapted from [43]). 
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2.1   Pathophysiology of AKI 
          The mechanisms of AKI have been well studied by researchers in recent decades. 
The understandings most derived from the work in animal models have provided 
promising insight into the underlying pathophysiology [44, 45]. Based on animal models 
of AKI that represent renal ischemia-reperfusion injury and nephrotoxicity, AKI is most 
likely to be a complicated disease that can be induced by several potential pathways and 
mechanisms of injury. Generally, the coagulation system is locally activated when the 
kidney has energy failure or renal cells are exposed to toxic medications [35, 46]. 
Leucocytes infiltrate the kidney [47], inflammatory cytokines and chemokines are released 
[48-50] and oxidative stress is activated [51]. The activation of coagulation, oxidative stress 
and inflammatory infiltration will further lead to vascular endothelial cell damage and 
microvascular congestion [52-54]. The sustained activation of these pathogenic factors will 
again amplify the inflammatory cascades, leading to apoptotic cell death [55, 56].  Some 
changes also occur on intracellular level such as loss of polarity [57] and adhesion to the 
basement membrane tubular cells [58]. Moreover, AKI induces distant organ dysfunction 
called organ cross-talk including liver, heart, lung and brain, emphasizing the complexity 
of its biological response [59, 60].           
2.1.1 Microvasculature Injury  
          The renal microvasculature plays a key role in determining vascular tone, leukocyte 
function in the pathophysiology of AKI [61]. Kidney is an organ with a high energy 
demand but a relatively low net oxygen extraction, which makes it susceptible to the 
changes of renal oxygen during any vascular ischemia and perfusion [48]. In healthy state, 
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adequate oxygen supply to the kidney is necessary for homeostatic control of renal 
function by the production of mitochondrial adenosine triphosphate (ATP), nitric oxide 
(NO) and reactive oxygen species (ROS) [62]. Once the kidney is injured, microvasculature 
system is damaged and the balance between ATP, NO and ROS is broken, leading to a 
series of subsequent pathogenic effects such as hypoxia and oxidative stress. The 
endothelial cells are activated and express new cell surface markers due to damage of 
microvascular endothelium and changes in the glycocalyx, which further promote the 
recruitment and adhesion of leukocytes and platelets, change oxygen delivery and trigger 
additional inflammation and endothelial cell injury [63, 64]. In addition, oxygen delivery 
and supply can be influenced by increase in vascular permeability, and production of 
vasoconstrictive prostaglandins and oxidative stress by injured tubule cells [63, 64]. The 
reduction in vascular endothelial growth factor (VEGF) and increase in transforming 
growth factor beta (TGF-β) signaling pathways would result in reduced density of 
peritubular capillary that is responsible for the development of hypoxia and renal fibrosis 
[65].   
2.1.2 Inflammation 
          Immune response can be classified into two different types: innate immune system 
and adaptive immune system, both of which are essential for the initiation of 
pathophysiology of AKI. The innate immune system has cells that are already present in 
the body and responsible for fighting microbes at the early response to injury. Such cells 
include macrophages, neutrophils, dendritic cells (DCs), natural killer (NK) cells and 
natural killer T cells. Besides, soluble molecules and membrane-associated receptors such 
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as complement, cytokines and toll-like receptor (TLR) are also important contributors 
to tubular injury. On the other hand, the adaptive immune system is initiated by specific 
pathogens that are able to overcome innate immune defenses. It comprises DC maturation 
and antigen presentation, T lymphocyte activation and proliferation, as well as T to B 
lymphocyte interactions, which are normally silent.  
          It is well known that robust inflammation response is activated following renal 
ischemia reperfusion [66]. Such activation triggered by the damage of tubule cells includes 
not only innate immune response but also adaptive immune response. During reperfusion, 
blood rich in innate immune components passes through injured kidney and accelerates 
the renal damage. A number of pro-inflammatory cytokines and chemotactic cytokines, 
such as TNF-α, IL-1β, IL-6, TGF-β and ENA-78 (epithelial neutrophil-activating protein 
78), are synthesized and produced following renal ischemia reperfusion injury [66]. 
Cytokines have been proved to be responsible for both local and distant organ injury in 
AKI. Renal injury is attenuated during ischemic acute renal injury by means of direct 
blockade of certain cytokines [67, 68]. Additionally, leukocytes are recruited into the post-
ischemic kidney, leading to increase in vascular permeability and destruction of epithelial 
and endothelial cell integrity [69]. Meanwhile, the tubular injury also activates DCs and 
thus activates naïve T cells to proliferate in an antigen-specific fashion, implicating the 
initiation of adaptive immune response.  
2.1.3 Reactive Oxygen Species 
12	
 
          Kidney is an organ that can not only directly produce a small amount of ROS in 
the course of renal oxidative metabolism [70], but also is susceptible to the damage by 
ROS [71-73]. Healthy kidney tolerates ROS without any obvious adverse effects only if 
their concentration is maintained at a low level. However, excessive ROS produced by 
renal cells themselves or infiltrating cells ( neutrophils and macrophages) in injured 
kidney can contribute to, or even further exacerbate several types of renal cell damage [71, 
74]. During ischemia, the reduction of molecular oxygen within cells leads to intracellular 
and extracellular ATP depletion, producing increased ATP degradation products 
including adenosine, hypoxanthine, xanthine and a shift towards anaerobic metabolism 
[75]. However, on reperfusion, the initial increase in oxygen delivery amount exceeds the 
amount needed for cellular metabolism from anaerobic pathways back to aerobic 
pathways. The whole process would lead to generation of damaging free radicals and a 
wide variety of ROS are generated, including superoxide radical, hydrogen peroxide and 
hydroxyl radical.  
          ROS contribute to cellular signaling and further affect multiple aspects of cellular 
functions such as proliferation, migration, gene expression and apoptosis [76]. Generally, 
there are thought to be three main pathways for the generation of ROS during ischemia-
reperfusion injury: 1) conversion of xanthine dehydrogenase to xanthine oxidase, 2) 
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activation and 3) 
uncoupling of the mitochondrial electron transport chain. Several studies have 
demonstrated that treatment with antioxidants or free radical scavengers can diminish 
acute renal injury. Noiri et al. showed the protection effect on rat kidney against ischemia 
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by targeting inducible nitric oxide synthase with oligodeoxynucleotides [77]. Ma and 
colleagues reduced cisplatin-induced AKI using saikosaponin-D which acts as a ROS 
scavenger by inhibiting MAPK and NF-κB signaling pathways [78]. 
2.1.4 Apoptosis 
          Apoptosis, an energy-dependent and programmed cell death, is another major 
etiological factor of AKI, which occurs in epithelial cells when they are undergoing a 
severe renal injury. As shown in Scheme 2, the mechanisms of apoptosis are complex and 
can be divided into two major pathways during ischemic renal tubule cell injury: intrinsic 
and extrinsic pathways.  
          It is now widely accepted that mitochondria is a major site for apoptosis and plays 
an important role in determining and regulating intrinsic and extrinsic pro- and anti-
apoptotic process [79, 80]. During ischemic renal injury, stress-induced increase of 
mitochondrial permeability permits the production of free radicals [79], ATP depletion 
[80] and release of pro-apoptotic proteins, cytochrome c, and in turn activates caspase-9 
[81]. The mitochondrial permeability transition has been well recognized to be regulated 
by apoptotic effectors, Bcl-2 family proteins [82]. Bax and Bak are the pro-apoptotic 
members of Bcl-2 family proteins that increase mitochondrial membrane permeability and 
promote apoptosis, whereas Bcl-2 and Bcl-XL are anti-apoptotic factors that maintain 
mitochondrial integrity and thus suppress apoptosis. During renal ischemia-reperfusion 
injury, the Bax/Bcl2 ratio, a decisive factor for programmed cell death [83], is increased 
due to the activation of Bax [84, 85] and inactivation of Bcl2 [86, 87]. Inhibition of apoptosis 
by blocking caspase or Bcl-2 proteins in ischemia animal models motivated the 
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development of therapeutic treatments [88, 89].  Mei et al. made double knockout of Bax 
and Bak in mice kidney proximal tubules and found ameliorated apoptosis in unilateral 
urethral obstruction model. This finding indicated that Bax and Bak together play a key 
role in mediating intrinsic apoptosis in AKI [90]. 
          Extrinsic apoptosis pathway is induced by the binding of death receptors and death 
ligands of the tumor necrosis factor (TNF) family on the cell surface. Death receptors 
include Fas and tumor necrosis factor-alpha (TNF-α). Activation of such death receptors 
leads to activation of downstream caspases to induce apoptosis, such as caspase 8 and 
caspase 10 [91]. 
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Scheme 2. Major intrinsic and extrinsic signal pathways of apoptosis in renal cells exposed 
to stress (Adapted from [56]).  
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2.2 Diagnosis and Management of AKI 
          AKI clinical evaluation mostly includes two parts: history examination and 
thorough physical examination. These two examinations are critical for determining and 
categorizing AKI. The history examination should be divided into drug history and social 
history examinations. Drug history should be considered for any uses of over-the-counter 
formulations, herbal remedies, and recreational drugs. Any exposure to tropical disease 
should be taken as social history. For physical examination, fluid status of patients should 
be monitored, any signs of acute and chronic heart failure, as well as infections should be 
examined, any skin rashes can also indicate systemic illness. Laboratory evaluation 
should include parameters such as serum creatinine (Scr), blood urine nitrogen (BUN), 
electrolytes, complete blood count and differential urine output.  
          Due to the complexity of AKI, all medications that underwent clinical trial failed 
and there are no effective pharmacotherapies for treating AKI. So far the clinical 
management of AKI is still primarily supportive. The key to management is to correct 
hypovolemia and assure adequate renal perfusion through fluids resuscitation [92]. PBS 
or human albumin fluid are preferred for fluid resuscitation over hydroxyethylstarch 
because of its nephrotoxicity [93]. In addition, control of electrolyte imbalance is essential 
for prevention or treatment of AKI. Insulin and calcium gluconate and sodium 
polystyrene sulfonate (Kayexalate) are common methods that can be used to control 
electrolyte imbalances, such as hyperkalemia, hypermagnesemia, hyponatremia, 
hypernatremia and metabolic acidosis. Besides these treatments, some other auxiliary 
therapies should be involved simultaneously with standard management practices.  
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          When AKI has potentially life-threatening complications, such as uncontrolled 
symptomatic fluid overload, severe persistent metabolic disturbances and refractory 
hyperkalemia, renal replacement therapy is required [94, 95]. However, the timing of 
initiating renal replacement therapy is still debatable [96, 97] and the cost of dialysis is a 
major burden for patients and healthcare systems. Based on recent advances in renal 
injury and repair signaling pathways, several pharmacological agents including 
antioxidants, anti-apoptosis or anti-inflammatory agents, growth factors and vasodilators 
for improving renal functions have developed [98]. However, so far no pharmaceutical 
agents are successful in clinical trials [99-101].  
3. Animal Models of AKI 
          To better understand pathophysiological mechanisms or study pharmacological 
therapies of AKI, in vivo animal models are indispensable to mimic situation in human 
body [102]. There are various animal models of AKI have been developed and tested. The 
most commonly used animal models for AKI are renal ischemia-reperfusion (IR) model 
and nephrotoxicity model which is induced by drugs like cisplatin. The IR model can be 
divided into unilateral and bilateral renal IR model on the basis of the site of injury [103-
105]. The unilateral renal IR model can further be categorized as two subtypes: unilateral 
IR with contralateral nephrectomy [105, 106] or without contralateral nephrectomy [107, 
108]. Compared to unilateral IR model, the bilateral IR model is more common because it 
is better to mimic the condition of human pathology [109, 110]. However, compared with 
nephrotoxicity model, these models might have big variations leading to inconsistency in 
results.   
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4. Kidney-targeted Drug Delivery Systems 
          Nanoparticles have attracted increasing attention over the past few decades due to 
their effective diagnostic and therapeutic functions in several diseases, such as cancer. 
Nanoparticles can be engineered to improve delivery efficacy to focus by overcoming 
several barriers that are associated with systemic drug administration, thus minimize 
non-specific accumulation and side effect in other organs. Lots of carrier systems have 
been developed and employed to optimize nanoparticles for prolonged circulation time 
in blood, targeting to specific organs or cell types. [111-113]. For example, Yang and 
colleagues developed chitosan/siRNA nanoparticles that are not only taken up specifically 
by renal proximal tubule epithelial cells through megalin-mediated pathway, but also 
enable gene silencing in those cells [114]. Kooijmans et al. coated extracellular vesicles 
with nanobody-PEG-micelles, by which they improved poor cell specificity and increased 
circulation time in vivo [115]. 
          Given the lack of pharmacological therapies for AKI, the kidney-targeted drug and 
siRNA delivery has drawn much attention in recent decades in order to improve the 
delivery efficacy in kidney. Although numerous carrier systems have been commonly 
used and shown promising effect in several diseases, only a few carrier systems like 
prodrugs and macromolecular carriers are the most frequently used strategies to achieve 
the goal of kidney-targeted drug delivery due to the size restriction of glomerulus 
filtration barrier. Drug targeting to the proximal tubule cells, which are the primary 
injured site in AKI could provide better treatment by means of enhancing the therapeutic 
efficacy of drugs and lowering unwanted side effects in other organs. In general, it only 
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allows carrier systems with a hydrodynamic diameter less than 10 nm to reach the site 
[9]. However, some studies also showed contradictory results that inorganic nanoparticles 
with the size ranging from 12-16 nm [22] and single-walled carbon nanotubes with 
average diameter less than 10 nm and average size 100 to 500 nm [28-31] can pass through 
the filtration threshold. 
4.1 Polymeric Carrier Systems 
          Several studies have demonstrated that polymeric carriers had a potential to target 
kidney and might be good candidates for drug and siRNA delivery. The copolymers of 
N-vinylpyrrolidone with anionic maleic acid showed increased renal accumulation when 
compared with the unmodified polyvinylpyrrolidone (PVP) [116]. Another polymeric 
carrier that has widely been used for drug and siRNA targeting to kidney is low molecular 
weight chitosan (LMWC). 50% N-acetylated LMWC demonstrated the capability to 
specific target kidney [117, 118]. Afterwards, the LMWC-based carriers have been further 
explored and showed the potential for delivering drug and siRNA to kidney. 
Glucosamine, the fundamental unit of  LMWC, showed enhanced protective effect against 
renal ischemia-reperfusion injury after conjugated to triptolide [119]. Chitosan/siRNA 
nanoparticles also demonstrated therapeutic effect against unilateral ureteral obstruction 
induced kidney injury [120].  
4.1.1 Protein- and Peptide-based Carrier Systems 
          Low molecular weight proteins (LMWPs) and peptides were also extensively 
studied for renal delivery of therapeutic drugs. Lysozyme has a molecular weight of 14 
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kDa and can be freely filtered in the urine with a glomerular sieving coefficient of 0.8 
[121], followed by the reabsorption by the proximal tubule cells. Therefore, lysozyme is 
one of the most popular protein carriers and has been conjugated to various drugs for 
specific renal delivery. For example, Prakash et al. has coupled Y27632 to lysozyme and 
they found that Y27632-lysozyme specifically accumulated in the kidney. The ischemia-
reperfusion induced tubular damage was significantly inhibited after treatment of 
Y27632-lysozyme, which was indicated by decreased level of inflammation and fibrosis 
[122]. Although LMWPs showed promising ability as carrier systems for renal targeting, 
some defectiveness like cardiovascular toxicity and complexity in modification may 
hinder their applications.   
          Besides LMWPs, peptides are still widely studied in renal targeting drug delivery. 
Wischnjow et al. conjugated ciprofloxacin to the peptide-based drug carrier, (KKEEE)3K, 
and successfully demonstrated the high selectivity to renal proximal tubule cells, 
indicating the excellent renal targeting potential of the peptide carrier [123]. Janzer and 
colleagues found that the targeting specificity of (KKEEE)3K did not change after drug 
conjugation even with a multiple-drug loading of a model drug, α-lipoic acid. While other 
peptide molecules, such as (KKQQQ)3K, showed a total loss of kidney specificity. This 
finding demonstrated (KKEEE)3K as a promising carrier candidate for treatment of AKI 
[124]. 
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4.1.2 Prodrugs 
          Prodrugs are compounds that can only be activated in the body after cleavage of 
chemical bonds [125-127]. Small drug molecules usually have poor chemical or metabolic 
stability, low water solubility and obvious toxicity in non-specific organs. Hence, 
development of prodrugs can improve these disadvantages and further give rise to patent 
line extension.  
4.1.2.1 Folate Modified Prodrugs 
          Although the expression of folate receptors is well recognized in tumor cells [128, 
129], the folate receptors are expressed in the kidneys as well. Folate can be filtered by 
glomerulus and reabsorbed by renal tubule cells as the form of 5-
methylenetetrahydrofolate. Mathias and colleagues conjugated folic acid to diethylene 
triamine pentaacetic acid (DTPA) by an ethylenediamine spacer forming DTPA-folate 
conjugate [130]. They found the accumulation of the radiolabeled DTPA-folate in both 
kidneys was approximately 23 % of the injected dose per gram tissue 4 h post intravenous 
injection. There was about 90% of DTPA-folate conjugates reduced in the kidneys after 
pretreatment of folic acid, which indicating that folate receptors in kidneys played an 
important role in the renal uptake of DTPA-folate conjugates. The other similar 
biodistribution study of [99mTc](CO)3-DTPA-folate demonstrated a higher renal 
accumulation which is about 50% of injected dose per gram tissue 4 h post intravenous 
injection [131]. However, the application of folate targeting in kidneys has been limited 
since folate receptors are not only expressed by kidneys [132].  
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4.1.2.2 Amino Acid Modified Prodrugs 
          Some endogenous enzymes have relatively high concentration in kidneys and hence 
their substrates, such as L-decarboxylation and γ-glutamyltranspeptidase, can be utilized 
to conjugate small drugs for targeting proximal tubule cells. Wilk and co-workers 
conjugate γ-glutamyl with dihydroxyphenylalanine to give γ-glutamyl-dopamine 
(GGDA) [133]. Its biodistribution study indicated that, compared with the administration 
of an equivalent dose of dopamine, an increased accumulation of dopamine in the kidney 
was observed following GGDA oral administration to mice. Even though dopamine has 
been proved to have no therapeutic effect on renal disease in clinic [134], this type of drug 
carrier can be conjugated with other drugs for renal targeting. 
4.1.3 Nanoparticles 
          Besides above carrier systems, nanoparticles have a great potential as carriers for 
drug and siRNA delivery to kidney. Choi et al. demonstrated that nanoparticles with 
average hydrodynamic diameter of 75±25 nm have ability to target kidney mesangium by 
comparing renal distribution of polyethylene glycol (PEGylated) gold nanoparticles with 
different sizes [135]. Based on these findings, they first established the criteria of 
nanoparticles construction for targeting diseases associated with mesangium. Alidori and 
co-workers successfully delivered Trp53- and Mep1b-targeted siRNA to proximal tubule 
cells simultaneously using an ammonium-functionalized single-walled carbon nanotubes 
(fCNT) and mice lived longer with mitigated AKI [136]. In evaluation of pharmacokinetic 
profile of fCNT/siRNA nanoparticles in primates, it showed comparable to mice which 
would be a promising approach for clinical application. Another new finding broads the 
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effective treatment of AKI. Hu et al. designed dexamethasone-loaded E-selectin-
targeting sialic acid-PEG-dexamethasone conjugate micelles and this nanoparticles 
showed enhanced kidney accumulation due to specific interaction between sialic acid and 
E-selectin , resulting in anti-inflammatory efficacy for acute kidney injury [137].  
5. RNA Interference Therapy 
          RNA interference (RNAi) is a powerful gene silencing process which is guided by 
small RNAs including small interfering RNAs (siRNAs) and microRNAs (miRNAs) [138]. 
These small RNAs down regulate key gene expressions through sequence-specific 
degradation of mRNAs or inhibition of protein translation, by which the cell fate is 
determined [139-141]. In addition, the endogenous gene expression can also be 
suppressed by RNAi therapy [142, 143].   
5.1 Small Interfering RNA 
          Small interfering RNAs (siRNA) consist of 20-25 base pairs and downregulate the 
expression of sequence-specific gene by post-transcriptional gene silencing pathway [144, 
145]. Mechanistically, after entering cytoplasm siRNAs bind multiprotein RNA-inducing 
silencing complex (RISC) and then sequence-specifically target mRNA. The argonaute-2 
which is also called slicer further triggers the cleavage of mRNA, leading to gene silencing. 
Unlike other gene technologies, siRNAs have several unique advantages, such as high 
degree of specificity to mRNAs, non-immunogenic property and high resistance to 
ribonucleases. With the development of technology for high-throughput gene expression 
and more understanding in several diseases, siRNAs have received increasing attention 
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and become one of the most promising therapeutic method for gene therapy [146, 147]. 
Soutschek and co-workers overcame the obstacle of in vivo gene silencing by intravenous 
administrating siRNAs which are chemically stabilized by modification of 
phosphorothioate backbone and 2’-O-methyl sugar on both sense and antisense strands 
[148]. They demonstrated decreased mRNA level of apolipoprotein B (apoB) in liver and 
jejunum, reduced plasma levels of apoB protein, as well as reduced total cholesterol. 
Moreover, they silenced human apoB in a transgenic mouse model, which indicates the 
promising potential for siRNAs in the treatment of human diseases.  
5.2 Carrier Systems for siRNAs Delivery 
          The employment of naked siRNA is always associated with several inherent 
problems due to the poor cellular permeability, easy degradation by endogenous enzymes 
and off-target effects [149]. To further increase the delivery efficiency of siRNAs to the 
targeted tissues in vivo, a wide variety of carrier systems have been developed [150, 151]. 
Carrier systems can be divided into two categories: viral carriers and non-viral carriers. 
The viral carriers have some advantages including high transfection effect and long-term 
gene expression while disadvantages such as high toxicity, immunogenicity and 
economic issue hinder the application.  
          Non-viral carrier systems such as cationic lipids and cationic polymers have drawn 
much attention in improvement of gene therapies. These cationic delivery systems form 
polyelectrolyte complexes with the oppositely charged siRNA. In general, cationic lipids 
are made up with inner aqueous compartment which contains siRNAs and outer 
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phospholipid bilayer. Cationic polymers, like chitosan, polyamidoamine, polypeptides 
are chemically synthesized and form complexes with siRNAs. Reddy et al. encapsulated 
paclitaxel and siRNA targeting Bcl-2 into a nanocarrier system which consists of kojic acid 
backbone-based cationic amphiphile [152]. By doing so, they successfully inhibited cell 
proliferation and thus reduced tumor growth, demonstrating an efficient method for 
systemic delivery of siRNA. For another example, Dahlman et al. synthesized epoxide-
modified lipid-polymer hybrids (7C1) for siRNA delivery to endothelium with high 
efficiency [153]. This formulation specifically reduced endothelial gene expression in lung 
to only 10% at a dose of 0.10 mg/kg and to 50% when the doses are as low as 0.02 mg/kg 
with no obvious gene expression decrease in other cells including luminary immune cells, 
hepatocytes and peritoneal immune cells. 7C1 nanoformulations should be a new 
candidate for siRNA delivery to endothelium in the future. 
6. Chemokines and Chemokine Receptors 
          Chemokines, also known as chemotactic cytokines, are small heparin-binding 
signaling proteins secreted by various stromal and epithelial cells and able to direct the 
movement of circulating leukocytes to inflammatory or injured sites via interacting with 
their respective chemokine receptors [154]. Chemokines and their receptors are well 
recognized as contributors for the pathogenesis of several diseases. And blockade of 
chemokine receptors has been used to regulate inflammation in many diseases. There are 
approximately 50 human chemokines which can be divided into four groups based on the 
number and spacing of N-terminal cysteines (Table 2) [155-157]. Among chemokines, CC 
chemokines are the largest family and have four cysteine residues with first two adjacent 
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to each other. CXC chemokines are the chemokines that have a single amino acid 
residue within the first two canonical cysteines. Fractalkine [158, 159] and lymphotactin 
[160] is the only member of the other two families, CX3C and XC respectively. There are 
19 different chemokine receptors that all belong to the seven-transmembrane G-protein-
coupled receptor family. Chemokines bind to their correspondent chemokine receptors 
on cell surface, by which signaling cascades are activated leading to cell rearrangement, 
change of shape or cell movement of action. 
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Table 2. CC, CXC, CX3C and XC Families of Chemokines and Chemokine Receptors 
(Adapted from [161]. Reproduced with permission from scientific reference citation, 
Copyright Massachusetts Medical Society). 
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Continued Table 2. CC, CXC, CX3C and XC Families of Chemokines and Chemokine 
Receptors (Adapted from [161]. Reproduced with permission from scientific reference 
citation, Copyright Massachusetts Medical Society). 
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6.1 CXCR4 and its Ligand SDF-1  
         C-X-C chemokine receptor 4 (CXCR4) is one of the most commonly expressed 
chemokine receptors in many tissues, which plays a vital role in the process of metastasis 
in multiple types of cancers and inflammatory diseases [162-165]. Binding with its ligand, 
stromal cell-derived factor-1 (SDF-1), divergent intracellular signaling transduction 
pathways are initiated, which can result in a variety of responses such as chemotaxis, 
cancer cell proliferation, recirculation and hematopoiesis of leukocytes [166, 167]. Driven 
by CXCR4 expressed in the primary tumor cells and leukocytes, the cells metastasize to 
secondary sites where SDF-1 is highly expressed, such as lung, liver, bone marrow, and 
brain [168]. For example, phosphatidylinositol-3-kinase (PI3K) pathway is activated by 
CXCR4/SDF-1 axis, leading to activation of protein kinase AKT, which is the key mediator 
in cancer cell migration and survival [169]. Moreover, the secretion of matrix 
metalloproteinases (MMPs) is increased and then extracellular matrix further degrades 
after CXCR4 activation, which facilitates the invasion process. Mitogen-activated protein 
kinase (MAPK) pathways is stimulated by CXCR4/SDF-1 axis as well, resulting in increase 
in cancer cell proliferation and survival [170].  Blocking the CXCR4/SDF-1 interaction by 
antagonizing CXCR4 can inhibit macrophage infiltration, induce tumor growth arrest and 
prevent metastatic spread [171, 172]. 
6.2 The Role of CXCR4 in AKI 
          Inflammation is a significant pathophysiological component of AKI [164, 173]. 
Cytokines and chemokines are involved in response to nephrotoxicity or reperfusion 
injury, leading to a proinflammatory microenvironment. CXCR4 and its ligand SDF-1 are 
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believed to be involved in recirculation and hematopoiesis of normal leukocytes, 
including neutrophils, monocytes and lymphocytes [167, 172, 174], which are key 
mediators of renal injury. Sustained high CXCR4 expression (on tubules or immune cells, 
such as macrophages), in turn, exacerbates renal injury and promotes necrosis. Inhibiting 
CXCR4 has been demonstrated to modulate immune system, leading to improved 
therapeutic activity of AKI [173, 175]. Zuk and co-workers showed renoprotective role of 
plerixafor (AMD3100) which is a small-molecule CXCR4 antagonist in renal ischemia-
reperfusion animal model [173]. After antagonizing CXCR4, plerixafor ameliorates AKI 
by modulating leukocyte infiltration and reducing expression of proinflammatory 
chemokines and cytokines.  
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Chapter 2. Determinants of synthetic polymeric carrier systems for renal-targeting 
in acute kidney injury 
1. Introductions 
          Drug targeting to the proximal tubule cells, which are the primary injured site in 
AKI could provide better treatment by means of enhancing the therapeutic efficacy of 
drugs and lowering unwanted side effects in other organs. Synthetic polymers are often 
used as carriers to target proximal tubular cells by means of either physically encapsulate 
or covalently conjugate drugs [176-178]. In recent years, several studies have been 
demonstrated that polymers have potential to target proximal tubular cells and might be 
good candidate for drug carriers. Kamada et al. demonstrated that polyvinylpyrrolidone-
co-dimethyl maleic anhydride [poly(VP-co-DMMAn)] had much higher accumulation 
and longer retention time in kidneys than native polyvinylpyrrolidone (PVP). The 
poly(VP-co-DMMAn)-modified superoxide dismutase also accelerated recovery from 
mercuric chloride-induced acute renal failure [179]. Mitra et al studied the biodistribution 
of N-(2-Hydroxypropyl) Methacrylamide (HPMA) copolymers with different molecular 
weight and charge [180]. They synthesized neutral and negatively charged HPMA 
copolymers with average molecular weights of 7 kDa, 21 kDa and 70 kDa. The negatively 
charged 21 kDa HPMA copolymers showed highest renal accumulation 24 h after 
intravenous injection in mice. These findings proved that the type and content of anionic 
groups introduced to the polymers, as well as polymer molecular weight play a vital role 
for renal cells targeting. However, the reported studies were performed in healthy 
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kidneys and very little is currently known about how physicochemical properties of 
polymers affect renal deposition in AKI. 
          Therefore, we synthesized and evaluated a library of polymers with a range of 
molecular weights and different net charges. We compared the cellular uptake and 
intracellular trafficking of polymers in mouse proximal tubular epithelial (MCT) cells at 
both normoxia and hypoxia conditions. Additionally, by testing biodistributions of each 
polymers in vivo, we explored and identified preferred polymer characteristics that 
preferentially accumulate in proximal tubular cells in AKI animal model.  
2. Materials and Methods 
2.1 Materials 
          N-(3-Aminopropyl) methacrylamide hydrochloride (APMA) and N-(2-
hydroxypropyl) methacrylamide (HPMA) were purchased from Polysciences, Inc. 
(Warrington, PA). Methacrylic acid (MAA) was obtained from Acros Organics (Belgium, 
NJ). 4, 4’-Azobis(4-cyanovaleric acid) (ACVA), 4-cyano-4-(phenyl carbonothioylthio) 
pentanoic acid (CPAD) which was as a typical CTA and fluorescein O-methacrylate (FMA) 
were from Sigma-Aldrich (St. Louis, MO). Cyclam (1,4,8,11-tetraazacyclotetradecane) was 
purchased from Alfa Aesar (Ward Hill, MA). N,N’-hexamethylenebisacrylamide (HMBA) 
was from Polysciences, Inc. (Warrington, PA). AMD3100 (base form) was from 
Biochempartner (Shanghai, China). RPMI medium 1640, Dulbecco’s phosphate buffered 
saline (PBS), and fetal bovine serum (FBS) were from Thermo Scientific (Waltham, MA). 
Mouse renal tubular epithelial cells (MCT) was a kind gift from Dr. Padanilam (University 
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of Nebraska Medical Center) and cultured in RPMI supplemented with 10% FBS. All 
other reagents were from Fisher Scientific and used as received unless otherwise noted. 
2.2 Methods 
2.2.1 Synthesis of Polymers 
          The polymerization was achieved at 70 °C, employing ACVA as the initiator and 
CPAD as the chain transfer agent. A typical protocol is as follows: APMA (178 mg, 1 mmol) 
was dissolved in doubly distilled water followed by the addition of CPAD (6.24 mg, 0.02 
mmol, target DPn = 45), ACVA (2 mg, 0.007 mmol) and FMA (7.15 mg, 0.018 mmol) in 1,4-
dioxane stock solution. The solution was added into a small glass vial and purged with 
nitrogen for at least 30 minutes. The vial was placed in an oil bath for polymerization at 
70 °C for 30 min, 3 h, and 4.5 h. After the polymerization, the solvent was dialyzed against 
water for 3 days before final freeze-drying.  
          The polymerization of pMAA and pHPMA was conducted employing similar 
procedure described above. The feed ratio, reagent and reaction time was according to 
Table 2.  
2.2.2 Polymer Characterizations 
          The molecular weights of pAPMA were analyzed by gel permeation 
chromatography (GPC) operated in 0.1 M sodium acetate buffer (pH 5.0) using Agilent 
1260 Infinity LC system equipped with a miniDAWN TREOS multi-angle light scattering 
(MALS) detector and a Optilab T-rEX refractive index detector (Wyatt Technology, Santa 
Barbara, CA). The column used was TSKgel G5000PWXL-CP (Tosoh Bioscience LLC, King 
of Prussia, PA) at a flow rate of 0.5 mL/min. Results were analyzed using Astra 6.1 
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software from Wyatt Technology. The degree of polymerization was calculated from 
the GPC. 
          The characterization of pMAA was conducted employing the same method but 
using AquaGel PAA-202 (London, ON, Canada) column. The characterization of pHPMA 
was conducted employing the same method but using 0.3 M sodium acetate buffer (pH 
5.0). 
          The amount of conjugated FMA was determined on a SpectraMax iD3 Multi-Mode 
Microplate Reader (Molecular Devices, CA). An amount of 1 mg of each dried polymers 
was dissolved in 1 ml PBS and the fluorescence intensity of the solution was measured at 
an excitation wavelength of 490 nm and an emission wavelength of 525 nm, which 
corresponds to a peak maximum for FMA. FMA content was determined by comparison 
to a FMA standard curve. 
2.2.3 Cellular Uptake and Intracellular Trafficking of Polymers 
          Flow cytometry analysis was conducted to study the cellular uptake of polymers. 
MCT cells (3 × 104) were seeded in 12-well plates and cultured to approximately 50% 
confluence. The cells were incubated in 37 °C at a virtual pAPMA concentration of 2 
µg/mL, pMAA concentration of 300 µg/mL or pHPMA concentration of 1 mg/mL for 24 h 
in either normoxic or hypoxic (2% O2) incubator. The cells were then washed with PBS 
twice, trypsinized and subjected to analysis using a BD FACS Calibur flow cytometer (BD 
Bioscience, Bedford, MA). The results were processed using FlowJo software.  
          Intracellular trafficking was observed by LSM 800 Laser Scanning Microscope (Zeiss, 
Jena, Germany). MCT cells were cultured on 24-well plates with round coverslip glass at 
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5 × 104 cells/well. After 24 h, the medium was exchanged with fresh medium and a 
solution of the studied polymers was added (same concentrations as cellular uptake). 
After incubation for another 24 h in either normoxia or hypoxia incubator, the cells were 
washed twice with PBS and fixed with 4% paraformaldehyde for 10 min and nuclei were 
stained with Hoechst 33258 for another 10 min.   
2.2.4 In vitro Cytotoxicity of the Polymers 
          Toxicity of the polymers was evaluated by Cell Titer Blue assay in MCT cells. The 
cells (5 X 103 cells/well) were plated in 96-well microplates. After 24 h, the cultured cells 
were treated with fresh medium and different polymers respectively. After further 24 h 
of incubation at either normoxic or hypoxic condition, the medium was removed and 
replaced with a mixture of 100 µL of serum-free media and 20 µL of CellTiter-Blue reagent 
(CellTiter-Blue Cell Viability Assay, Promega). After 2 h of incubation, the fluorescence 
(560/590 nm) was measured on a SpectraMax iD3 Multi-Mode Microplate Reader 
(Molecular Devices, CA). The relative cell viability (%) was calculated as 
[fluorescence]sample/[fluorescence]untreated X 100. 
2.2.5 Induction of Ischemia-reperfusion Kidney Injury 
          To induce AKI, we used the animal model of unilateral or bilateral renal ischemia-
reperfusion (I/R) injury. All animal experiments followed a protocol approved by the 
UNMC Institutional Animal Care and Use Committee. C57BL/6J male mice (8-10 week 
old) were purchased from Charles River. All animals were given free access to food and 
water. The non-fluorescent food was given at least 1 week before surgery. The mice were 
anesthetized by intraperitoneal administration of ketamine (200 mg/kg) and xylazine (16 
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mg/kg). For unilateral I/R injury, following left dorsal flank incision, renal pedicles were 
bluntly dissected and a microvascular clamp (Roboz Surgical Instrument, Gaithersburg, 
MD) was placed on the left renal pedicle for 30 min to induce unilateral I/R injury. During 
the procedure, mice were kept well hydrated with warm saline and on 37 °C heating pad. 
After 30 min of occlusion, the clamps were removed and kidney reperfusion was verified 
visually. Then wound clips were used to close skin. Sham-operated right side underwent 
the same surgical procedure, except for the occlusion of the renal arteries. The mice were 
monitored until they woke up. Similar procedure was conducted to induce bilateral I/R 
injury by placing microvascular clamp on both renal pedicle for 30 min. Sham-operated 
control animals also underwent the same surgical procedure, except for the occlusion of 
the renal arteries. 
2.2.6 In vivo Biodistribution of Polymers 
          Biodistribution of the polymers in I/R mice was analyzed by ex vivo fluorescence 
imaging. Each different polymers were administered via tail vein injection 24 h post-
surgery. At 4 h and 24 h after administration, mice were killed and major organs were 
isolated and imaged using Xenogen IVIS 200. Emission wavelength of 540 nm and 
excitation wavelength of 500 was used to image organs. The fluorescence intensities from 
liver and kidney was quantified using  Living Image® 4.5 software. The radiant efficiency 
of the kidney and liver was measured as (photons/sec/cm2/sr)/(µW/cm2). Background 
fluorescence was subtracted prior to analysis. To study intracellular localization of 
different polymers in kidney, bisected kidneys were embedded in OCT compound and 
cut into 10 µm frozen sections. The frozen sections were either stained with DAPI, or 
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stained with haematoxylin and eosin (H&E). Polymer localizations were visualized by 
LSM 800 Laser Scanning Confocal Microscope (Zeiss, Jena, Germany).  Histopathological 
change was confirmed by H&E sections under EVOS microscope. 
2.2.7 Tissue Homogenization 
          To quantify the amounts of polymers in I/R kidneys and sham-operated kidneys, 
kidneys dissected from C57BL/6J mice bodies were finely minced with scissors and placed 
in a homogenizer vessel.  750 µL RIPA buffer and HaltTM protease & phosphatase inhibitor 
cocktail were added and tissues were subsequently homogenized. Homogenized samples 
were centrifuged at 15,000 rpm for 15 min at 4 °C.  The supernatant was used to quantify 
polymer amount in kidneys by standard addition method using a fluorescence Symergy 
2 Microplate Reader (BioTek, VT).  
2.2.8 Statistical Analysis 
          Data are presented as the means ± SD. The statistical significance of the mean values 
of all groups was determined by using one-way ANOVA. An unpaired t test was used to 
compare the means of two different groups. A P value < 0.05 was considered statistically 
significant. 
3. Results and Discussions 
3.1 Polymer Synthesis and Characterization  
          Polymers such as HPMA, APMA or MAA have been used as carriers of drugs and 
siRNA to enhance their stability in vivo and as targeted delivery systems. Lots of low-
molecular weight therapeutic agents show improved activity when conjugated to or 
encapsulated into carrier systems containing such polymers [181-183]. Because the 
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biodistribution of such therapeutic agents is influenced by the properties of the carrier 
system, we developed a library of 9 fluorescently labeled polymers, including neutral 
pHPMA, negatively charged pMAA, and positively charged pAPMA, with reversible 
addition-fragmentation chain-transfer (RAFT) polymerization method to evaluate 
properties both in vitro and in vivo. Table 3 shows the RAFT polymerization condition of 
pAPMA, pMAA and pHPMA, in which polymers are prepared by copolymerization of 
the corresponding monomers with a fluorescein-containing co-monomer using CTA 
transfer agent and ACVA initiator at 70°C. The feed ratio of monomer/CTA/ACVA/FMA 
is variable according to different monomers. All polymers are characterized by GPC. The 
molecular weight range is from 5 kDa to 36 kDa with a low Mw/Mn value (Table 3). The 
fluorescence of the synthesized polymers is used to track the subcellular fate and 
distribution of the polymers both in vitro and in vivo. The content of FMA is quantified for 
each polymers (Table 3) in order to enable the comparison of fluorescence data obtained 
from the different polymers.  The GPC curves for all polymers are shown in Figure 1.  
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Table 3. Polymer Characterizations 
a. Initial molar ratio of monomer/CTA/ACVA/FMA 
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Figure 1. GPC curves of all polymers.  
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3.2 Cellular Uptake and Intracellular Trafficking of Polymers 
          For many applications of RAFT generated polymers in biopharmaceutical use, 
potential for toxicity is a concern. Therefore, it is important to understand toxicity of 
polymers in MCT cells, mouse renal proximal tubule cells, before conducting cellular 
uptake. To evaluate cytotoxicity of polymers, CellTiter Blue assay was conducted in MCT 
cells (Table 4). Because we used unilateral renal ischemia-reperfusion injury model 
(explained below) to study biodistribution of polymers in vivo, we evaluated cytotoxicity 
at both normoxia and hypoxia conditions. We found there was no obvious toxicity after 
we incubated MCT cells with pHPMA at 1 mg/mL at both normoxia and hypoxia 
regardless of size. The HPMA based copolymers have been extensively examined as 
biocompatible, non-immunogenic and non-toxic drug carriers [184, 185]. For pMAA and 
pAPMA, generally the smaller was the size, the less toxic was the polymers. And IC50 at 
hypoxia was generally lower than normoxia, which may result from more cellular uptake 
of polymers at hypoxia. pAPMA showed much higher toxicity to MCT cells due to highly 
positive charges.  
          In order to compare uptake of polymers in vitro at normoxia and hypoxia, we 
investigated the cellular uptake of different polymers. MCT cells were selected and 
incubated with the polymers for 24 h and cellular uptake was determined by flow 
cytometry. The mean fluorescence intensity (MFI) ratio between normoxia and hypoxia 
was showed in Figure 2. For pAPMA, cells had similar MFI after incubated at either 
normoxia or hypoxia. Among pMAA, the fold of MFI for pMAA-5 was ~ 2.8, while 
pMAA-16 and pMAA-31 didn’t show much diverse cell uptake at normoxia and hypoxia. 
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For pHPMA with all three sizes, more polymers were taken up by MCT cells at hypoxia 
and the highest ratio was observed with pHPMA-36, which was about 4 folds. 
          Flow cytometry yields semi-quantitative results for fluorescence taken up by cells 
or attached to their outer membrane, therefore we used confocal laser scanning 
microscopy to verify intracellular trafficking of each polymers. Similarly, the cells were 
incubated with different polymers for 24 h and then imaged by confocal microscopy 
(Figure 3). All polymers were clearly observed inside the cells. They were internalized 
into the cells and mainly localized in the cytoplasm. Compared with normoxia, there was 
no difference observed for cellular trafficking of pAPMA at hypoxia. For pMAA, a slightly 
higher intensity was only observed for pMAA-5 after hypoxic incubation. However, the 
fluorescence intensities in cytoplasm of pHPMA with all sizes were significantly increased 
after cells were incubated at hypoxia. And the most significant difference was also 
observed with pHPMA-36. These results of cellular uptake and intracellular trafficking 
indicated that MCT cells had increased cell uptake at hypoxia for certain polymers, such 
as smallest sized pMAA (pMAA-5) and those three pHPMA polymers at hypoxia, which 
prompted us to further investigate the distribution in vivo.  
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Table 4. IC50 of different polymers in MCT cells at normoxia or hypoxia condition. Cell 
viability was measured by CellTiter blue after 24 h incubation at 37 °C. 
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Figure 2. Cellular uptake of different polymers in MCT cells. Quantification of cellular 
uptake is shown by mean fluorescence intensity (MFI) ratio between cells incubated at 
hypoxia and at normoxia after 24 h. Data were shown as the mean ± SD (n = 3).  
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Figure 3. Intracellular trafficking of different polymers in MCT cells by confocal 
microscopy after 24 h incubation (63X).  
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3.3 Renal accumulation of polymers in unilateral I/R mice 
          Polymer size and charge play an important role in kidney deposition because 
glomerulus basement membrane filters small molecules by size and charge. Generally, in 
healthy state, molecules with hydrodynamic diameter less than 5-7 nm or molecular 
weight less than 68 kDa can pass this barrier. However, the barrier can be broken by 
podocyte effacement in disease and large or charged molecules could accumulate in the 
Bowman space due to the leaky and abnormal fenestrae after renal ischemia [186-188]. 
Therefore, we hypothesized that renal targeting of polymers can be impacted by AKI and 
this impact can be associated with size or charge of polymers.  
          To understand how AKI affects the biodistribution, especially for renal 
accumulation, of polymers with different sizes and charges, we established a well-known 
kidney injury model, unilateral ischemia-reperfusion (I/R) model, where left renal artery 
was clamped and renal injury was induced in the left kidney while the right kidney was 
also exposed and remained intact. Mice were sacrificed at two designated time points, 4 
h or 24 h post intravenously administration and major organs were isolated for ex vivo 
fluorescence imaging (Figure 4A). Generally, we didn’t find any less polymers entering 
into I/R kidneys due to reduced blood perfusion as compared to sham-operated kidneys 
at these two time points. In contrast, we found polymers with certain size and charge 
showed relative more accumulation in I/R kidneys at 24 h. Among negatively charged 
pMAA and neutral pHPMA, pMAA-5 and pHPMA-36 showed most distinct 
accumulation in I/R and sham-operated kidneys at 24 h. Region of interest (ROI) ratio 
between I/R and sham-operated kidneys of these two polymers at 24 h was ~ 4, and the 
47	
 
renal accumulation was similar at 4 h (Figure 4B). The higher the molecular weight of 
pMAA (pMAA-16 and pMAA-31) or the lower the molecular weight of pHPMA 
(pHPMA-5 and pHPMA-16), the less the fluorescence difference between I/R and sham-
operated kidneys at 24 h. Sluggish and occasionally retrograde blood flow after I/R injury 
and delayed clearance of macromolecules from the injured kidneys may lead to the 
delayed and increased accumulation at 24 h [189, 190]. Pathological change of kidneys 
after I/R injury, e.g. endothelial dysfunction, can also contribute to change in interaction 
between macromolecules and kidneys at cellular level [189, 191]. These polymers did not 
appear to be taken up to a significant extent by any organ other than kidneys, especially 
for the two major organs of reticuloendothelial system, liver and spleen (Figure 4A & 6C). 
In contrast, for positively charged polymers pAPMA, we didn’t observe any obvious 
difference between I/R and sham-operated kidneys, except for high liver accumulation of 
pAPMA-16 at 4 h and pAPMA-30 at 24 h. Positively charged macromolecules are usually 
susceptible to rapid renal elimination and high non-specific uptake in liver [23, 24]. These 
results indicated that AKI has size-, and charge-dependent effect on renal uptake of 
synthetic polymers. Its potential to take more pMAA-5 and pHPMA-36 may provide us a 
new angle of view to design polymeric carrier systems for renal targeting in AKI.  
          To quantify the amount of polymers in I/R and sham-operated kidneys and make 
sure that the fluorescence observed from IVIS was from fluorescent labeled polymers, 
instead of the auto-fluorescence of the tissues, plate-reader was used to detect 
fluorescence in the tissue homogenates. Considering the possible auto-fluorescence from 
these tissues, we analyzed these data using standard addition (Figure 5). On the basis of 
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homogenized tissues, it is evident that the ratio of each polymers amount between I/R 
and sham-operated kidneys was consistent with the ROI ratio from IVIS results shown 
above. The highest ratio of polymers between I/R and sham-operated kidneys was 
observed in pMAA-5 and pHPMA-36, which accorded with previous IVIS results. 
          To further understand this selective accumulation of polymers with different sizes 
and charges in I/R kidney, we conducted intracellular localization and histological studies 
on the both I/R and sham-operated kidney with frozen sections and H&E staining, 
respectively (Figure 6). In sham-operated kidneys, even though kidneys had been exposed 
to polymers, kidney tissues remained normal. For I/R kidneys, extensive tubular 
dilatation and cast formation were found in cortex. According to confocal pictures, we 
found in I/R and sham-operated kidneys all the 9 polymers passed glomerular filtration 
barrier into Bowman space and finally can be taken up by proximal tubule cells in some 
extent. The molecular weights of these polymers are less than 68 kDa which is a threshold 
for macromolecules to cross this barrier. Even though basement membrane has negative 
charge, it does not impact on the filtration of these polymers in either I/R or sham-
operated kidneys. When getting into Bowman space, majority of positively charged 
pAPMA may be susceptible to rapid renal clearance and be quickly eliminated from 
kidney, while the excretion of negatively charged pMAA and neutral pHPMA from cortex 
to renal pelvis might be limited in I/R kidneys [189, 192] and such polymers can be 
selectively reabsorbed and sustained by renal tubule cells which are damaged during AKI.  
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Figure 4. Biodistribution of pAPMA, pMAA and pHPMA in mice with unilateral I/R 
injury at the indicated time points. (A) Ex vivo imaging of dissected organs at 4 or 24 h 
after administration, which indicating lung, heart, liver, spleen, left kidney and right 
kidney (from left to right and top to bottom). Region-of-interest (ROI) ratios of left to right 
kidney (B), or ROI ratio of left kidney to liver (C) at indicated time points were quantified. 
Data were shown as the mean ± SD (n = 5). **, p < 0.01. 
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Figure 5. Quantification of different polymers in left and right kidneys. Kidneys were 
homogenized and the fluorescence of each sample was measured by standard addition 
method. A-C) pAPMA-6, pAPMA-16 and pAPMA-30; D-F) pMAA-5, pMAA-16 and 
pMAA-31; G-I) pHPMA-5, pHPMA-16 and pHPMA-36. Data are shown as mean ± SD (n 
= 5).  
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Figure 6. Confocal microscopy images (20X) and H&E staining (20X) of kidney sections. 
Kidneys were extracted from mice with unilateral I/R injury receiving pAPMA-6, 
pAPMA-16 or pAPMA-30. 
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Continued Figure 6. Confocal microscopy images (20X) and H&E staining (20X) of kidney 
sections. Kidneys were extracted from mice with unilateral I/R injury receiving pMAA-5, 
pMAA-16 or pMAA-31. 
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Continued Figure 6. Confocal microscopy images (20X) and H&E staining (20X) of kidney 
sections. Kidneys were extracted from mice with unilateral I/R injury receiving pHPMA-
5, pHPMA-16 or pHPMA-36. 
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3.4 Validation of Renal Accumulation in Bilateral I/R Kidney Injury Model 
          Based on previous results, we had two concerns. First, are these results reproducible? 
Second, is unilateral I/R injury model comparable to bilateral renal I/R injury model in 
this study? Bilateral renal I/R injury model is most frequently used in experimental study 
because it is a clinically relevant model to study the AKI. However unilateral renal I/R 
injury animal model provides us lots of benefits in renal accumulation study. For example, 
it can avoid individual difference and reduce the risk of mortality due to the functional 
redundancy [193]. To verify that our results are also applicable to bilateral I/R animal 
model as well as repeat the results, we selected two polymers, pAPMA-30 and pHPMA-
16. We selected pAPMA-30 because we didn’t find any effect of AKI on its accumulation 
in kidneys. On the contrary, pHPMA-16 in I/R kidneys was ~ 3.5 times as much as it was 
in sham-operated kidneys (Figure 4B & 5H). Considering the relatively large standard 
deviation in pHPMA-36 (Figure 4B), we did not select it although the variation of 
fluorescence intensity between I/R and sham-operated kidneys was slightly bigger. To 
evaluate renal accumulation of pAPMA-30 and pHPMA-16 in bilateral I/R animal model, 
similar procedure was performed. As demonstrated in Figure 7B, a strong fluorescent 
signal was observed in I/R kidneys after administration of pHPMA-16 at 4 h and it was 
sustained at 24 h. Similar to the result from unilateral I/R model, pAPMA-30 showed no 
preference to accumulate in the I/R kidneys at both 4 h and 24 h (Figure 7A). In addition, 
compared with sham-operated kidneys, quantified fluorescence intensity of I/R kidneys 
increased to ~2.1 folds and ~2.5 folds for pHPMA-16 at 4 h and 24 h, respectively, on the 
basis with ROI ratio. Alteration in renal hemodynamics for unilateral and bilateral renal 
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I/R injury model might contribute to the differences in renal accumulation of pHPMA-
16 at 4 h. But parallel results were seen in these two animal models that polymers 
potentially accumulate in I/R kidneys in unilateral renal I/R model also tend to accumulate 
in I/R kidneys in bilateral renal I/R model, and vice versa. Hence, this study confirmed 
our previous results and indicated that unilateral I/R animal model can be a viable model 
for us to investigate renal accumulation of polymers in AKI.  
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Figure 7. Biodistribution of pAPMA-30 and pHPMA-16. I/R mice or sham-operated mice 
were given one injection of pAPMA-30 or pHPMA-16 at 24 h post-surgery. Ex vivo 
imaging of pAPMA-30 (A) and pHPMA-16 (B) were taken at 4 h or 24 h after 
administration. Organs were lung, heart, liver, spleen, left kidney and right kidney (from 
left to right and top to bottom). (C) Quantified ratio of ROI between kidneys from I/R mice 
and sham-operated mice. Data are shown as mean ± SD (n = 3).  
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4. Conclusion 
          In summary, unilateral renal I/R injury model allowed us to obtain the 
understanding that AKI alters renal accumulation of polymers with various sizes and 
charges. Our data suggested that polymers that showed the most enhanced ability to 
accumulate in I/R kidneys were negatively charged pMAA-5 and neutral pHPMA-36. 
These new findings provide not only advance our fundamental understandings of 
transport of polymeric drug delivery systems in normal and injured kidneys, but also 
initial insights on the polymeric drug delivery systems to AKI. 
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Chapter 3. Exploring the Potential of CXCR4/SDF-1 Chemokine Axis in the 
Treatment of Acute Kidney Injury 
1. Introduction 
          Acute kidney injury (AKI) is characterized by a sudden loss of renal function with 
high morbidity and mortality [42, 194, 195]. AKI affects over 13 million patients 
worldwide every year and remains a global public health concern [35]. It is a difficult-to-
prevent medical problem which involving complexed biological process, such as 
vasoconstriction, leukostasis, immune activation and apoptosis [56, 196, 197]. AKI may 
finally lead to chronic kidney disease and ultimately kidney failure [40], in which case the 
patient would require expensive renal dialysis or transplantation [198].  
          As opposed to treating the damage per se, current treatment methods for AKI can 
only slow down the progress of the condition. The management is mainly focused on 
supportive treatment by achieving and maintaining hemodynamic stability and avoiding 
hypovolemia to assure adequate renal perfusion [199]. When AKI has potentially life-
threatening complications renal replacement therapy is required [94, 95]. Several 
pharmacological agents have developed on the basis of recent advances in renal injury 
and repair signaling pathways, such as recombinant alkaline phosphatase, p53 siRNA and 
levosimendan [98]. However, no pharmaceutical agents are successful in clinical trials so 
far. Given the complex pathogenesis of AKI and lack of treatment of AKI, it might be 
necessary to develop therapies that simultaneously targets multiple pathways [200].  
          siRNA has received increasing attention as a therapeutic approach for treating 
various diseases through silencing specific genes [201-203].  Unlike other gene 
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technologies, siRNAs have several unique advantages, such as high degree of 
specificity to mRNAs [204], non-immunogenic property [205] and high resistance to 
nucleases [206]. Several studies successfully ameliorate AKI by inhibiting gene expression 
with siRNA. Kim and co-workers in the same group used hydrodynamic injection method 
to inhibit Tp53-induced glycolysis and apoptosis regulator (TIGAR) expression. By doing 
so, they showed renoprotective effect on ischemic kidney injury [207]. However, the 
hydrodynamic injection produces high pressure during administration which will lead to 
liver damage and local renal dysfunction. Therefore, this method cannot be used in large 
animals and humans [208]. To safely and efficiently deliver siRNAs to kidneys, limited 
studies developed carrier systems and successfully attenuated AKI. Alidori and co-
workers selectively delivered siRNAs targeting both p53 and Mep1b with ammonium-
functionalized carbon nanotube (fCNT) to renal tubule cells in AKI and the renal injury 
was significantly ameliorated [136]. Yang et al. also prevented kidney damage by using 
chitosan/siRNA nanoparticles targeting cyclooxygenase type 2 (COX-2) [120]. Thus, using 
polymeric carrier systems to deliver siRNA in kidneys may be one of promising pathways 
for therapeutic strategy for AKI. 
          Cytokines and chemokines are elevated in response to AKI, leading to a 
proinflammatory microenvironment [157]. C-X-C chemokine receptor 4 (CXCR4) is one 
of the most commonly expressed chemokine receptors in many tissues, which plays a vital 
role in the process of inflammatory diseases or the metastasis in multiple types of cancers 
and [162-165]. Binding with its ligand, stromal cell-derived factor-1 (SDF-1), divergent 
intracellular signaling transduction pathways are initiated, which can result in a variety 
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of responses such as chemotaxis, cancer cell proliferation, recirculation and 
hematopoiesis of leukocytes [166, 167]. Emerging evidence shows that the increased 
chemokine receptor CXCR4 and its ligand SDF-1 are involved in the AKI pathology [164]. 
The CXCR4/SDF-1 axis is implicated in regulating trafficking and invasion of 
inflammatory cells in the injured kidneys. The inhibition of the axis appears to exert 
beneficial therapeutic effect in experimental AKI animal models [173, 175]. For example, 
Yuan et al, demonstrated that the mouse renal fibrosis was attenuated after administration 
of AMD3100 which is CXCR4 antagonist [175]. Therefore, interference the CXCR4/SDF-1 
signaling pathway will be another promising therapeutic method for the treatment of AKI.         
          In this study, we report the development of a novel combinational therapeutic 
strategy for treatment of AKI based on previously synthesized dual-function polymeric 
CXCR4 inhibitors (PCX) which is also capable of systemically delivering siP53 to kidneys 
with AKI. Our previous study suggested that PCX was able to function in such a dual 
manner [209]. Here, we hypothesized that the PCX/siP53 polyplexes will lead to an 
improved therapeutic effect on AKI through dual pathways of antagonizing CXCR4 and 
down regulating p53.  
2. Materials and Methods 
2.1 Materials 
          Cyclam (1,4,8,11-tetraazacyclotetradecane) was obtained from Alfa Aesar (Ward 
Hill, MA). N,N’-hexamethylenebisacrylamide (HMBA) was from Polysciences, Inc. 
(Warrington, PA). Trifluoroacetic acid (TFA) was purchased from ACROS Organics (Fair 
Lawn, NJ). RPMI 1640 medium, Dulbecco’s phosphate buffered saline (PBS), and fetal 
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bovine serum (FBS) were from Thermo Scientific (Waltham, MA). Mouse 
glyceraldehyde 3-phosphate dehydrogenase siRNA (siGAPDH sense, 5’-
CAGAAGACUGUGGAUGGCC (DTDT)-3’, antisense, 5’-
GGCCAUCCACAGUCUUCUG(DGDG)-3’) were purchased from GE Healthcare 
Dharmacon, Inc. (Lafayette, CO). Cyanine 3 (Cy3) NHS ester and Cyanine 5.5 (Cy5.5) NHS 
ester were from Lumiprobe （Hunt Valley, MD）. Rotor-Gene SYBR Green RT-PCR Kit 
was from QIAGEN (Hilden, Germany). TRIzol® reagent was purchased from Life 
Technologies (Carlsbad, CA). Mouse CXCR4 primers (Forward, 5’-
CTGTGACCGCTTCTACCCCAATGACTT-3’, Reverse, 5’-CTTGGGGTAGGAGATACG 
AAAGGAACC-3’) and GAPDH primers (Forward, 5’- AACGACCCCTTCATTGAC-3’, 
Reverse, 5’-TCCACG ACATACTCAGCAC-3’) were purchased from Sigma-Aldrich. The 
normalized primers of phosphoglycerate kinase 1 (PGK1) (Forward, 5’-GCAGATTGTT 
TGGAATGGTC-3’, Reverse, 5’-TGCTCACATGGCTGACTTTA-3’) were from Real Time 
Primers. All other reagents were from Fisher Scientific and used as received unless 
otherwise noted.  
2.2 Methods  
2.2.1 Synthesis and Characterization of PCX Polymer  
          The process of synthesis and characterization of PCX followed our previous 
published method [209].  
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2.2.2 Preparation and Characterization of PCX/siRNA Polyplexes 
          PCX/siRNA polyplexes were prepared in 10 mM HEPES buffer (pH 7.4) at 
predetermined w/w ratios by mixing equal volume of PCX and siRNA solutions. The 
polyplexes were allowed to form at room temperature for 20 min before use.  Polyplexes 
prepared at different PCX-to-siRNA weight ratios were loaded (20 µL of the sample 
containing 1.0 µg of microRNA) and run for 30 min at 75 V in 0.5 × Tris/Borate/ EDTA 
buffer. The gels were visualized under UV illumination on a KODAK Gel Logic 100 
imaging system. 
          siRNA release from polyplexes was analyzed by heparin displacement assay. The 
polyplexes were prepared at a w/w ratio of 10 and incubated with increasing 
concentrations of heparin for 30 min at room temperature. The samples (20 µL of the 
sample containing 0.5 µg of siRNA) were then analyzed by agarose gel electrophoresis.  
          Hydrodynamic diameter and ζ -potential were determined by dynamic light 
scattering using a ZEN3600 Zsizer Nano-ZS (Malvern Instruments Ltd., Massachusetts, 
United States). Results were expressed as mean ±  standard deviation (SD) of three 
experimental runs for each sample. The morphology of complexes was observed by 
transmission electron microscopy (TEM, Tecnai G2 Spirit, FEI Company, USA). 
2.2.3 Cellular Uptake and Intracellular Trafficking of PCX/siRNA Polyplexes 
          Flow cytometry analysis was used to study the cellular uptake of polyplexes. MCT 
cells (105) were seeded in 12-well plates. On the other day, the cells were incubated with 
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PCX/FITC-Oligo polyplexes at a FITC-Oligo concentration of 50 nM for 4 h. The cells 
were then trypsinized, washed with PBS and subjected to analysis using a BD 
FACSCalibur flow cytometer (BD Bioscience, Bedford, MA). The results were processed 
using FlowJo software. 
          Intracellular trafficking was observed by LSM 800 Laser Scanning Microscope (Zeiss, 
Jena, Germany). MCT cells were cultured on 24-well plates with round coverslip glass at 
5 × 104 cells/well. After 24 h, a solution of polyplexes prepared at different w/w ratios was 
added at FITC-Oligo concentration of 50 nM. After incubation for another 4 h, the cells 
were washed twice with PBS and fixed with 4% paraformaldehyde for 10 min and nuclei 
were stained with Hoechst 33258 for another 10 min.   
2.2.4 Induction of Kidney Injury 
          To induce AKI, two different animal models were used, unilateral I/R injury and 
cisplatin-induced injury. All animal experiments followed a protocol approved by the 
UNMC Institutional Animal Care and Use Committee. For unilateral I/R injury, CD-1 
male mice (8-10 week old) were purchased from Charles River. All animals were given 
free access to food and water. The non-fluorescent food was given at least 1 week before 
surgery. The mice were anesthetized by intraperitoneal administration of ketamine (200 
mg/kg) and xylazine (16 mg/kg). Following left dorsal flank incision, renal pedicles were 
bluntly dissected and a microvascular clamp (Roboz Surgical Instrument, Gaithersburg, 
MD) was placed on the left renal pedicle for 35 min to induce unilateral I/R injury. During 
the procedure, mice were kept well hydrated with warm saline and on 37 °C heating pad. 
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After 35 min of occlusion, the clamps were removed and kidney reperfusion was 
verified visually. Then wound clips were used to close skin. Sham-operated right side 
underwent the same surgical procedure, except for the occlusion of the renal arteries. The 
mice were monitored until they woke up. Cisplatin nephrotoxic AKI was induced in CD-
1 male mice (aged 8–10 weeks). Mice were intraperitoneally injected with a single dose of 
cisplatin at 15 mg/kg after starvation for 18 h.  
2.2.5 In vivo Biodistribution of Polymers 
          Biodistribution of the polymers in mice with cisplatin-induced injury was analyzed 
by ex vivo fluorescence imaging. siRNA was labeled with Cy5.5 and PCX polymers were 
labeled with Cy3. Free PCX-Cy3, free siRNA-Cy5.5 or polyplexes were administered via 
tail vein injection 72 h after cisplatin administration. At 4 h and 24 h after administration 
of free PCX-Cy3, free siRNA-Cy5.5 or polyplexes, mice were sacrificed and major organs 
were isolated and imaged using Xenogen IVIS 200 at designated emission and excitation 
wavelength. The fluorescence intensity from kidney was quantified using Living Image® 
4.5 software. The radiant efficiency of the kidney was measured as 
(photons/sec/cm2/sr)/(µW/cm2). Background fluorescence was subtracted prior to analysis. 
To study intracellular localization of different polymers in kidney, bisected kidneys were 
embedded in OCT compound and cut into 10 µm frozen sections. The frozen sections 
were either stained with DAPI, or stained with H&E. The localizations of free siRNA-
Cy5.5, free PCX-Cy3 and polyplexes were visualized by LSM 800 Laser Scanning Confocal 
Microscope (Zeiss, Jena, Germany).  Histopathological change was confirmed by H&E 
sections under EVOS microscope. 
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2.2.6 Renal Function Deterioration 
          Blood was collected for BUN (QuantiChromTM Urea Assay Kit, BioAssay Systems, 
USA) and creatinine (QuantiChromTM Creatinine Assay Kit, BioAssay Systems, USA) 
measurements. Kidneys were dissected for paraffin embedding and for qRT-PCR. 
Paraffin sections (4 mm) were stained with periodic acid-Schiff (PAS) by tissue facility at 
UNMC. Histopathological change was confirmed by PAS sections under EVOS 
microscope. 
2.2.7 RNA Isolation and Quantitative Reverse Transcription PCR (qRT-PCR) 
          The expression mRNA levels of CXCR4 and GAPDH were evaluated by TaqMan 
qRT-PCR. Kidneys and other tissues were homogenized in TRIzol® reagent (Life 
Technologies, Carlsbad, CA) according to manufacturer’s protocol for total RNA 
extraction. 2 µg of total RNA was converted into cDNA using High Capacity cDNA 
Reverse Transcription Kits. The obtained cDNA then served as the template for qRT-PCR 
using the iTaqTM Universal SYBR Green kit (BIO-RAD) running on a Rotor-Gene Q 
instrument (QIAGEN) according to the manufacturer’s instructions. mRNA expression 
levels were expressed relative to the internal control according to the comparative 
threshold cycle (Ct) method. Primers used for qRT-PCR amplification are specified in 
Materials. 
2.2.8 Statistical Analysis 
          Data are presented as the means ± SD. The statistical significance of the mean values 
of all groups was determined by using one-way ANOVA. An unpaired t test was used to 
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compare the means of two different groups. A P value < 0.05 was considered statistically 
significant. 
3. Results and Discussions 
3.1 CXCR4 Expression in Kidneys with AKI 
          Chemokines are vital of importance in inflammation. They provide chemoattractive 
signals for leukocytes activation and migration [210]. The increase in expression of CXCR4 
in the injured kidneys has been reported by several papers [164, 211]. Here, we showed 
renal CXCR4 mRNA and protein level in kidneys after unilateral I/R injury. We induced 
IR injury on left kidney (I/R kidney) while the right kidney received sham surgery (healthy 
kidney). At the designated time points after surgery, we conducted paraffin sections from 
healthy and IR kidneys to determine the CXCR4 protein level by immunohistochemistry 
analysis. The relative mRNA level was determined by qRT-PCR analysis followed by 
RNA extraction. For cisplatin-induced mouse model, similar procedures were conducted 
at 72 hours after cisplatin administration. The CXCR4 staining in healthy kidney showed 
undetectable expression (Figure 8A), while it showed a positive patchy pattern in I/R 
kidney and cisplatin injured kidney. Based on Figure 8A, we can see tubule cells are 
CXCR4 positive while glomerulus is CXCR4 negative. There is more intense staining in 
distal tubule compared to proximal tubule cells. H&E staining confirms the 
pathophysiology of healthy and injured kidneys. Figure 8B is the relative CXCR4 mRNA 
level in IR kidney and cisplatin injured kidney. For I/R kidney, CXCR4 mRNA level shows 
a gradient increase along with time passing. At 1 day after surgery, the CXCR4 mRNA 
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level in I/R kidney is 1.6 times as much as that in healthy kidney. At 13 days after 
surgery, the CXCR4 mRNA level in I/R kidney is about 4.2 times more than that in healthy 
kidney.  
          Based on the result of CXCR4 protein and relative mRNA level, we concluded that 
the CXCR4 expression increases in the kidney with unilateral I/R animal model. The 
increased CXCR4 in I/R kidney does not show obvious effect on the CXCR4 level in the 
contralateral healthy kidney. 
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Figure 8. Characterization of CXCR4 expression in kidney with AKI. (A) H&E staining 
and CXCR4 immumostaining for healthy and I/R kidney. (B) Relative CXCR4 mRNA level 
in I/R kidney. Data are shown as mean ± SD (n = 3). 
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3.2 Preparation and Characterization of PCX/siRNA Polyplexes 
          The ability of PCX to form polyplexes with siRNA was evaluated by agarose gel 
electrophoresis assay. In Figure 9A, there was a smear band at w/w ratio of 0.5 and 1. PCX 
can fully condense siRNA at a w/w ratio of 2 or above as indicated by no fluorescence 
signal coming out of the well. The ability of PCX/siRNA polyplexes to release siRNA was 
then evaluated by heparin displacement assay (Figure 9B).  For PCX/siRNA polyplexes 
prepared at w/w 5, the siRNA was not fully released until the heparin concentration was 
80 µg/mL, which means the polyplexes were able to release siRNA. 
          Hydrodynamic size and zeta-potential of PCX/siRNA polyplexes prepared at 
various w/w ratios were measured by dynamic light scattering (Figure 9 C&D). 
Polyplexes prepared at w/w 2 showed a relative large size with around 300 nm while the 
size decreased to ~127 nm at w/w 5 and ~107 nm at w/w 10. Polydispersity indexes (PDI) 
was less than 0.2 for all the three formulations. As expected, due to the redundant cationic 
PCX around the surface of polyplexes, increasing the w/w ratio to make polyplexes leads 
to the increased zeta-potential. The morphology of PCX/siRNA polyplexes was confirmed 
by transmission electron microscopy (TEM). Nice sphere shape of PCX/siRNA polyplexes 
prepared at all the three w/w ratios was observed under TEM （Figure 9E）. 
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Figure 9. Characterization of polyplexes of PCX/siRNA. (A) siRNA condensation by 
PCX in 10 mM HEPES buffer (pH 7.4) using agarose gel electrophoresis. (B) Heparin 
induced siRNA release from the polyplexes. Polyplexes were prepared at w/w 5 and 
incubated with increasing concentrations of heparin. (C) DLS size distribution of 
PCX/siRNA. (D) Zeta-potential of PCX/siRNA. (E) TEM images of PCX/siRNA. Data 
are shown as mean ± SD (n = 3). 
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3.3 Intracellular localization and Cellular Uptake of PCX/siRNA polyplexes 
          To study the intracellular localization and cellular uptake, the siRNA used to form 
polyplexes with PCX was labeled with FAM fluorescence. MCT cells were treated with 
PCX/FAM-siRNA for 4 h followed by fixation for confocal microscopy. Cell nuclei were 
stained with Hoechst 33258 which was indicated by blue color. As shown in Figure 10A, 
for PCX/FAM-siRNA prepared at all the three w/w ratios, the most fluorescence of FAM-
siRNA was distributed in cytoplasm while no fluorescence was observed in the cell 
nucleus.           
          Next, we investigated the cellular uptake of PCX/siRNA polyplexes prepared at 
various w/w ratios. MCT cells were incubated with the PCX/FAM-siRNA polyplexes for 
4 h and cellular uptake was determined by flow cytometry. As shown in Figure 10B, the 
significantly increased mean fluorescence intensity (MFI) indicated that PCX polyplexes 
had significant cellular uptake in MCT cells when compared with untreated cells or cells 
treated with free FAM-siRNA. The cell uptake increased when the w/w ratios in 
preparation of the polyplexes increased from 2 to 10. The percentage of cells that taken up 
the polyplexes (Figure 10C) showed similar trend as MFI data. PCX/siRNA polyplexes 
prepared at w/w ratio of 10 were selected for subsequent in vivo study as their highest 
cell uptake.   
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Figure 10. Intracellular trafficking and cellular uptake of PCX/siRNA polyplexes. (A) 
Intracellular trafficking of PCX/FITC-siRNA in MCT cells by confocal after 4 h of 
incubation. Quantification of cellular uptake is shown by (B) mean fluorescence 
intensity (MFI) and (C) % cell uptake. Data are shown as mean ± SD (n = 3). 
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3.4 Biodistribution of PCX/siRNA polyplexes in vivo 
          Accumulation of polyplexes in focus is the prerequisite for therapeutic treatment. 
Before measuring therapeutic effect of PCX/siRNA polyplexes, it is necessary to study the 
biodistribution of the polyplexes in AKI mouse model.  
          To understand whether PCX/siRNA polyplexes can target injured kidneys, the 
biodistribution of polyplexes was conducted. The mouse model we used to study 
biodistribution is well-established mouse model, cisplatin-induced nephrotoxic injury. To 
track polyplexes, we labeled PCX with Cy3 and siRNA with Cy5.5. Mice were sacrificed 
at two designated time points, 4 h or 24 h post intravenously administration and major 
organs were isolated for ex vivo fluorescence imaging by IVIS. As shown in Figure 11A, a 
slightly more fluorescence of free siRNA was in healthy kidneys at 4 h after administration 
and most siRNA was excreted from kidneys at 24 h after injection. On the contrary, 
significant fluorescence of siRNA of polyplexes was observed in injured kidneys 
compared with healthy kidneys. No obvious fluorescence was shown in other organs 
except for the weak signal in liver and spleen. Quantification of fluorescence of siRNA 
was shown in Figure 11B. For polyplexes, the fluorescence intensity increased 
approximately by 50% in injured kidneys compared with healthy kidneys at 4 h post 
injection. However, there was no difference between healthy and injured kidneys after 
free siRNA administration.   
          As shown in Figure 11C, the PCX showed potential to accumulate in injured kidneys 
for both free PCX and polyplexes. At 24 h, most PCX of polyplexes was excreted while 
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free PCX remained in injured kidneys. No obvious fluorescence was shown in other 
organs except for the weak signal in liver and spleen. Fluorescence quantification showed 
that, at 4 h post injection, the fluorescence intensity of PCX of polyplexes in injured 
kidneys was ~7 times as much as that in healthy kidney (Figure 11D).  
        Given the complex structure of kidney, we were further interested in suborgan 
distribution of the polyplexes. To investigate the intracellular localization of PCX/siRNA 
polyplexes, frozen kidney sections were visualized under confocal microscopy. As shown 
in Figure 12A, most polyplexes cross glomerulus filtration barrier and accumulate in 
injured mouse tubule cells at 4 h after intravenous administration. Enlarged fenestration 
of filtration barrier in injured kidney may allow large polyplexes to pass through this 
barrier. An alternative possibility is that polyplexes could disassemble at glomerular 
basement membrane and a fraction of PCX reassociate with siRNA after filtrating into 
urinary space and facilitate uptake of siRNA in tubule cells [114]. The yellow dots in 
merged images indicated intact polyplexes. The ability of renal tubule cells to uptake 
systemically injected siRNA has been well-known and extensively used [212, 213]. As 
expected, free siRNA passed glomerulus filtration barrier and accumulated in mouse 
tubule cells of both healthy and injured kidney at 4 h after intravenous administration 
(Figure 12B). The intracellular localization of free PCX in kidneys was evaluated as well 
(Figure 12C). Consistent with IVIS result, a lot of PCX accumulated in injured kidney 
while few PCX accumulated in healthy kidney. In injured kidney, large amount of PCX 
crossed glomerulus filtration barrier and distributed in tubule cells other than glomeruli 
which is indicated by white arrow. 
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        Based on above results, we confirmed that PCX/siRNA polyplexes are able to 
specifically target renal tubule cells in cisplatin-induced nephrotoxic mouse model, which 
prompted us to further investigate the in vivo transfection efficacy of PCX/siRNA.  
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Figure 11. Biodistribution of PCX/siRNA polyplexes in healthy mice and cisplatin-injured 
mice. Ex vivo imaging of dissected organs at 4 or 24 h after administration of free siRNA 
(A) and polyplexes (B). Excitation wavelength is 675 nm and emission wavelength is 720 
nm. Organs include heart, lung, liver, spleen and kidneys (from left to right and top to 
bottom). Quantification of fluorescence of siRNA-Cy5.5 from free siRNA (C) and 
polyplexes (D) was shown. 
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Continued Figure 11. Biodistribution of PCX/siRNA polyplexes in healthy mice and 
cisplatin-injured mice. Ex vivo imaging of dissected organs at 4 or 24 h after 
administration of free siRNA (A) and polyplexes (B). Excitation wavelength is 535 nm and 
emission wavelength is 580 nm. Organs include heart, lung, liver, spleen and kidneys 
(from left to right and top to bottom). Quantification of fluorescence of PCX-Cy3 from free 
PCX (C) and polyplexes (D) was shown. 
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Figure 12. Confocal microscopy images of kidney sections. Kidneys were extracted from 
mice with healthy and cisplatin-induced injury at 4 h after receiving polyplexes (A), free 
siRNA (B) and free PCX (C). Glomeruli is indicated by white arrow. Magnification, 20X. 
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3.5 In vivo transfection effect of PCX/siRNA polyplexes 
        Silencing specific gene expression in kidneys by siRNA through systemic 
hydrodynamic injection is a common method for siRNA delivery in rodents [207, 214]. 
Hydrodynamic injection via systemic circulation can cause transient high pressures in 
veins during rapid injection of a large volume, leading to enhanced delivery of siRNA 
into organs with high blood flow, such as kidneys and liver [215, 216]. Although this 
method has been proven useful for a wide range of application in rodents, it is not feasible 
in humans due to the possible cardiac congestion [217]. Based on above biodistribution 
result of PCX/siRNA polyplexes, therefore, we will further measure silencing efficacy of 
the polyplexes in vivo. We chose glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
as target gene due to its stable expression in the body. Procedure of experiment is shown 
in Figure 13A. 1.67 mg/kg (50 µg) siGAPDH dose was used for hydrodynamic injection. 
1.12 mg/kg (0.28 mg/kg ´ 4, free siGAPDH and w/w 5) and 0.56 mg/kg (0.14 mg/kg ´ 4, 
w/w 10) siGAPDH doses were used for polyplex injections. To avoid individual difference 
and reduce the risk of mortality of mice, we established a unilateral IRI model, where left 
renal artery was clamped and renal injury was induced in the left kidney while the right 
kidney was also exposed and remained intact. After treatment, as shown in Figure 13B, 
there was approximately 25% down regulation of GAPDH mRNA in injured kidneys 
treated with PCX/siGAPDH prepared at w/w 5. The silencing efficacy of PCX/siGAPDH 
was slightly better than hydrodynamic injection, but the siGAPDH dose of 
PCX/siGAPDH was only two thirds of the dose of hydrodynamic injection. One study 
reported there was about 40% of GAPDH silencing in kidneys after hydrodynamic 
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injection with an approximate siGAPDH dose of 7.5 mg/kg and other organs such as 
spleen and liver also showed detectable GAPDH silencing [218]. There was no obvious 
silencing for free siGAPDH although its dose was same to polyplexes prepared at w/w 5. 
For polyplexes prepared at w/w 10, only about 18% down regulation of GAPDH mRNA 
level due to less injected siGAPDH amount.  
        In summary, the polyplexes of PCX/siGAPDH prepared at w/w 5 showed a 
significant GAPDH silencing in targeted injured kidney at an extremely low siGAPDH 
amount. This finding is promising for further therapeutic study of polyplexes in AKI. 
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Figure 13. Silencing efficacy of PCX/siGAPDH polyplexes in unilateral ischemia-
reperfusion mouse model. Experiment was conducted followed the procedure in (A). The 
relative GAPDH mRNA level was measured after treatment (B). Data are shown as mean 
± SD (n = 3) 
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3.6 In vivo Therapeutic Effect of PCX/siRNA Polyplexes 
          Results from the distribution study of PCX/siRNA complexes gave us enough 
confidence to proceed to investigate the therapeutic efficacy of our formulations as a 
preconditioning therapy for AKI. First, we evaluated the therapeutic efficacy of PCX only 
in the cisplatin-induced animal model. As shown in Figure 14A, mice were 
prophylactically treated for four consecutive days with PCX, AMD3100 or PBS. On the 
third day, mice received a single nephrotoxic dose of cisplatin to induce AKI (15 mg/kg). 
Blood was collected on day 4 and day 5 for renal function study. Then mice were sacrificed 
on day 5 and kidneys were collected for PAS staining of paraffin sections. Based on the 
level of BUN and Creatinine in Figure 14 B&C, AMD3100 and our PCX polyplexes didn’t 
show any obvious nephrotoxicity in healthy mice. For mice induced AKI by cisplatin, the 
BUN and Creatinine level significantly reduced after the treatment of AMD3100 and PCX, 
which indicated that antagonism of CXCR4 has renoprotective effect on AKI. However, 
the renal protective effect was similar between AMD3100 and our PCX polymers.  
          Histological analysis of kidneys from those mice was performed. PAS stained 
kidneys from healthy mice receiving AMD3100 or PCX showed normal tissue 
morphology. The morphology of kidneys from injured mice receiving AMD3100 or PCX 
also showed consistence with healthy control mouse tissue (Figure 15A). The percentage 
of damaged tubules were quantified and shown in Figure 15B.  
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Figure 14. Therapeutic effect of PCX. Animal experiment was conducted in cisplatin-
induced injury model. The timeline was shown in (A). Renal function deterioration was 
evaluated by BUN (B) and serum creatinine (C).  
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Figure 15. Histological evaluation of the effect of PCX on tubule damage in response to 
cisplatin-induced AKI. (A) Representative images of PAS staining of kidney sections (20X). 
(B) PAS analysis of renal tubule damage (PBS, n = 3; AMD3100, n = 4; PCX, n = 5)  
 
 
Ci
sp
lat
in
+P
BS
Ci
sp
lat
in
+A
M
D3
10
0
Ci
sp
lat
in
+P
CX
0
20
40
60
Pe
rc
en
ta
ge
 o
f d
am
ag
ed
 tu
bu
le
s 
PBS AMD3100 PCX 
Cisplatin+PBS Cisplatin+AMD3100 Cisplatin+PCX 
A 
B 
85	
 
4. Conclusion 
          In summary, PCX/siRNA could be specifically delivered into injured kidney 
following intravenous injection, where it can persist for about 24 h. Treatment with PCX 
can mitigate AKI. And injections of very low doses of GAPDH siRNA showed similar 
silencing effect to hydrodynamic injection. These data presented here provide a potential 
generic platform of gene therapy for treatment of AKI and may further augment the 
potential clinical application of siRNA for AKI. In the future, the pathophysiological roles 
of this novel pharmacological approach will be evaluated in several proteins 
overexpressed during AKI.  
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Chapter 4. Conjugate polyplexes with anti-invasive properties and improved 
siRNA delivery in vivo 
1. Introduction 
          siRNA has received increasing attention as therapeutic approach for treating 
various diseases through silencing specific genes [201-203]. The use of naked 
unformulated siRNA, however, is associated with several inherent problems due to the 
poor cellular permeability, easy degradation by endogenous enzymes and off-target 
effects [149]. To efficiently deliver siRNAs to the target tissues in vivo, a wide variety of 
non-viral carrier systems, such as cationic lipids and cationic polymers, have been 
developed to form polyelectrolyte complexes with the oppositely charged siRNA [150, 
151]. These cationic carriers provide high transfection efficiency in vitro but suffer from 
low activity in vivo. The cationic carriers may not form sufficiently strong interactions with 
anionic siRNA simply through electrostatic interactions because of the relatively small 
size of siRNA [219, 220]. Polycations have a tendency to interact with multiple proteins in 
serum and cause aggregation which can lead to fatal disseminated intravascular 
coagulation-like condition [221-223]. In addition, because of their dynamic nature, 
polyplexes are susceptible to disassembly by various competing biomacromolecules in 
the systemic circulation or at a glomerular basement membrane in the kidneys by the 
action of heparan sulfate [224-230]. Many solutions have been proposed to the premature 
systemic disassembly, including modifications with hydrophobic residues and covalent 
crosslinking of the particles [224, 231-233]. To overcome the limitations of siRNA in 
effective electrostatic condensation with polycations, polymerized siRNA was used and 
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shown to form stable polyplexes with efficient intracellular translocation and targeted 
gene silencing in vitro [234, 235]. Finally, direct covalent linkage of siRNA to synthetic 
polymers can significantly improve the performance during systemic siRNA delivery 
[236-238].  
          Human serum albumin (HSA) is the most abundant protein in human body. HSA is 
involved in many important biological functions, such as delivery of nutrients from 
circulating system to cells and maintenance of osmotic pressure and vascular integrity. As 
a natural transport protein, HSA is able to bind with various endogenous and exogenous 
molecules [239, 240]. In addition, its target specificity for glycoprotein 60 receptor, which 
is presented on the surface of cancer cells, allows potential site-specific delivery of various 
anti-cancer agents. Several studies also showed that albumin-based drug delivery systems 
can accumulate in solid tumors and facilitate tumor targeting due to passive targeting by 
enhanced permeability and retention (EPR) effect [241, 242]. Albumin has been also 
explored in improving the safety and efficacy of polyplexes. Because of its negative net 
charge, albumin has been utilized to coat polyplexes with the goal to avoid hepatic 
accumulation, reduce toxicity and improve delivery of therapeutic nucleic acids [240, 243]. 
PEI/DNA polyplexes coated with albumin showed improved gene transfer efficiency with 
negligible toxicity [244-246]. Stable ternary polyplexes were developed by modification of 
PEI with ligands for albumin binding [247]. Interestingly, even unmodified HSA 
improved the internalization and silencing efficiency of PEI/siRNA polyplexes in cancer 
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cells [248]. Unfortunately, very few studies report on the use of albumin-coated 
polyplexes in vivo.  
          CXCR4 is one of the most commonly expressed chemokine receptors, which plays 
a vital role in the process of metastasis in multiple types of cancer [249]. Binding with its 
ligand, stromal cell-derived factor-1 (SDF-1), divergent intracellular signaling 
transduction pathways are initiated, which can result in a variety of responses such as 
chemotaxis, cancer cell proliferation, migration and invasion [166]. Driven by CXCR4 
expressed in the primary tumor cells, the cells metastasize to secondary sites where SDF-
1 is highly expressed, such as lung, liver, bone marrow and brain [250]. Blocking the 
CXCR4/SDF-1 interaction by antagonizing CXCR4 can inhibit macrophage infiltration, 
induce tumor growth arrest and prevent metastatic spread [165, 172]. We previously 
reported the synthesis of hyperbranched bioreducible polycationic CXCR4 inhibitors 
named rPAMD [251-254]. The rPAMD had the ability to inhibit cancer cell invasion as a 
result of their CXCR4 inhibitory activity, while mediating efficient transfection in vitro. To 
further advance development of rPAMD for systemic delivery of siRNA, we hypothesized 
that conjugating thiol-modified siRNA to rPAMD will enhance stability against 
disassembly and that coating of such conjugates with HSA will decrease the positive 
surface charge and enhance safety of the formulations (Scheme 1). Here, we have tested a 
simple thiol-disulfide exchange conjugation strategy to prepare rPAMD-SS-siRNA 
polyplex conjugates and tested their stability in serum and against heparin exchange. 
Reporter gene silencing activity of the polyplex conjugates was tested in B16F10-luc 
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mouse melanoma cells to determine how the covalent conjugation and HSA coating 
affects the silencing efficacy. Finally, the systemic siRNA delivery efficacy of the 
developed polyplex conjugates was tested in vivo in a syngeneic tumor model. 
2. Materials and Methods 
2.1 Materials 
          AMD3100 base form was purchased from Biochempartner (China). N,N’-cystamine-
bisacrylamide (CBA) was obtained from Polysciences, Inc. (Warrington, PA). Ethidium 
bromide (EtBr) was from Fisher Bioreagents (Fair Lawn, N.J.). Dithiothreitol (DTT) was 
obtained from Alfa Aesar (Heysham, LA3 2XY, England). Scrambled siRNA (siScr, sense: 
5’-AUG AAC GUG AAU UGC UCA AUU-3’), luciferase siRNA (siLuc, sense: 5’-GGA 
CGA GGA CGA GCA CUU CUU-3’), thiol-modified scrambled siRNA (siScr-SH, sense: 
5’-S-S-AUG AAC GUG AAU UGC UCA AUU-3’), thiol-modified luciferase siRNA (siLuc-
SH, sense: 5’-S-S-GGA CGA GGA CGA GCA CUU CUU-3’) were custom-synthesized by 
Dharmacon, GE, and deprotected by tris(2-carboxyethyl) phosphine hydrochloride (TCEP) 
solution following the manufacturer’s instructions. Dulbecco’s Modified Eagle Medium 
(DMEM), RPMI-1640 Medium, Dulbecco’s Phosphate Buffered Saline (PBS), and Fetal 
Bovine Serum (FBS) were from Thermo Scientific (Waltham, MA). Cell culture inserts for 
24-well plates with 8.0 µm pores (Translucent PET Membrane, cat# 353097) and BD 
MatrigelTM Basement Membrane Matrix (cat# 354234) were obtain from BD Biosciences 
(Billerica, MA). Human SDF-1 was from Shenandoah Biotechnology, Inc. (Warwick, PA). 
All other reagents were from Fisher Scientific and used as received unless otherwise noted. 
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2.2 Methods 
2.2.1 Synthesis and Characterization of rPAMD 
          rPAMD was synthesized through Michael-type polyaddition with equal molar ratio 
of AMD3100 and a reducible bisacrylamide CBA [253]. Briefly, AMD3100 (100.4 mg, 0.4 
mmol) and CBA (52 mg, 0.4 mmol) were dissolved in methanol/water mixture (2 mL, 7/3 
v/v). The reaction was stirred under nitrogen at room temperature for 48 h. Excess 
AMD3100 (10 mg) was added to react with any residual CBA acrylamide groups. After 6 
h of continuous stirring, 1.25 M HCl was added dropwise to the mixture until the pH 
reached 4. The resulting HCl salt of rPAMD was collected and dialyzed (molecular weight 
cut-off 3.5 kDa) against acidified water (pH 4) for 3 days before final lyophilization. 1H-
NMR was used to confirm the chemical composition of the synthesized rPAMD and 
AMD3100 content in the polymers. The completion of the reaction was validated by the 
disappearance of the acrylamide peak of CBA. The weight- and number-average 
molecular weights, as well as the polydispersity index (PDI, Mw/Mn) was characterized by 
gel permeation chromatography (GPC) operated in 0.1 M sodium acetate buffer (pH 5.0) 
using Agilent 1260 Infinity LC system equipped with a miniDAWN TREOS multi-angle 
light scattering (MALS) detector and a Optilab T-rEX refractive index detector (Wyatt 
Technology, Santa Barbara, CA). The column used was Tosoh Bioscience TSKgel 
G3000PWXL-CP eluted at a flow rate of 0.5 mL/min. Results were analyzed using Astra 
6.1 software from Wyatt Technology.   
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2.2.2 Preparation and Characterization of HSA-coated Polyplexes   
          rPAMD/siRNA polyplexes were prepared in 5 mM HEPES buffer (pH 7.4) at 
predetermined w/w ratios by mixing equal volume of rPAMD and siRNA solutions. The 
polyplexes were allowed to form at room temperature for 20 min before use. Similarly, 
rPAMD-SS-siRNA conjugate polyplexes were prepared by mixing of rPAMD and siRNA-
SH in 5 mM HEPES buffer (pH 7.4) and kept at room temperature for 2 h before use. To 
prepare HSA-coated polyplexes, which are named as HSA[rPAMD/siRNA] and 
HSA[rPAMD-SS-siRNA], HSA solution in 5 mM HEPES buffer (pH 7.4) was added to the 
prepared polyplexes or conjugate polyplexes at a HSA/rPAMD w/w ratio of 5. The 
mixture was allowed to stand at room temperature for 20 min before use. Hydrodynamic 
diameter and ζ-potential were determined by dynamic light scattering using a ZEN3600 
Ζsizer Nano-ZS (Malvern Instruments Ltd., Massachusetts, United States). Results were 
expressed as mean ± standard deviation (SD) of three experimental runs for each sample. 
2.2.3 Agarose Gel Electrophoresis 
          Polyplexes were prepared as above and incubated with increasing concentrations of 
heparin with or without 10 mM DTT. 18 µL of each sample (siRNA concentration: 20 
µg/mL) were loaded onto a 2.5% agarose gel containing 0.5 µg/mL EtBr and run for 30 
min under electrophoresis at 75 V in 0.5X Tris/Borate/EDTA (TBE) running buffer. Free 
siRNA of the same concentration was used as the control. The gel was then visualized 
under UV. 
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2.2.4 Cell Culture 
          Human epithelial osteosarcoma U2OS cells that stably express functional EGFP-
CXCR4 fusion protein were obtained from Fisher Scientific and cultured in DMEM 
supplemented with 2 mM L-glutamine, 1% Pen-Strep, 0.5 mg/mL G418 and 10% FBS. 
Mouse melanoma cell line B16F10 expressing luciferase (B16F10-luc) was purchased from 
PerkinElmer and maintained in RPMI with 10% FBS. 
2.2.5 Cytotoxicity 
          Cytotoxicity of the polyplexes and conjugate polyplexes was determined by Cell 
Titer Blue assay. The cells were plated in 96-well plates at a density of 10,000 cells/well 
(B16F10-luc) and 8,000 cells/well (U2OS). The next day, the culture medium was removed 
and replaced by 150 µL of serum-free medium containing polyplexes or conjugate 
polyplexes prepared at w/w 2 and 5 (rPAMD concentration was 2, 8 and 15 µg/mL for 
B16F10-luc cells and 2 µg/mL for U2OS cells). For B16F10-luc, the medium was replaced 
with fresh growth medium after 4 h incubation and the cells were cultured for another 48 
h. For U2OS, the cells were incubated with polyplexes or conjugate polyplexes for 16 h. 
Then, the medium in each well was removed and a mixture of 100 µL serum-free media 
and 20 µL of CellTiter-Blue reagent (CellTiter 96®Aqueous Non-Radioactive Cell 
Proliferation Assay, Promega) was added. After 1 h incubation, the fluorescence (F) was 
measured using Synergy 2 Microplate Reader (BioTek, VT) at an excitation wavelength of 
560 nm and an emission wavelength of 590 nm. The relative cell viability (%) was 
calculated as [F]sample/[F]untreated X 100%.  
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2.2.6 CXCR4 Redistribution Assay 
          U2OS cells overexpressing EGFP-CXCR4 were plated in black 96-well plates with 
optical bottom 24 h before experiment at a density of 8000 cells per well. On the day of the 
assay, cells were washed twice with 100 µL assay buffer (DMEM supplemented with 2 
mM L-Glutamine, 1% FBS, 1% Pen-Strep and 10 mM HEPES). Then different formulations 
(2.0 µg/mL of polymer) or AMD3100 (300 nM) were added in the assay buffer containing 
0.25% DMSO and incubated with cells for 30 min at 37°C. SDF-1 was then added to each 
well to make the final concentration 10 nM and cells were incubated at 37°C for another 1 
h. After incubation, 4% formaldehyde at room temperature for 20 min, followed by 4 times 
of PBS washing and staining with 1 µM Hoechst 33258 for 30 min. Fluorescent microscopy 
was conducted using EVOS fluorescence microscope (20x). High content analysis was 
used to quantify the internalization of CXCR4 receptors using Cellomics ArrayScan VT1 
Reader and SpotDetector V3 BioApplication software. CXCR4 inhibitory activity of 300 
nM AMD3100 was considered as positive control and set as 100% and cells treated with 
SDF-1 only was set as 0%. CXCR4 activity of all the tested particles was expressed as mean % 
inhibition ± SD (n = 3).  
2.2.7 Cell Invasion Assay 
          Each transwell insert was coated with 40 µL diluted ice-cold Matrigel (1:3 v/v with 
serum-free medium) and placed in 37°C incubator for 2 h prior to experiment. CXCR4+ 
U2OS cells were trypsinized and resuspended in serum-free medium containing 
AMD3100 (300 nM), rPAMD/siRNA, HSA[rPAMD/siRNA], rPAMD-SS-siRNA or 
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HSA[rPAMD-SS-siRNA] (rPAMD 2.0 µg/mL). 100,000 treated cells in 300 µL medium 
were added to each insert, and 20 nM SDF-1 in serum-free medium was added to the 
corresponding wells in the companion plate as the chemoattractant. Cells were allowed 
to invade through the Matrigel layer towards SDF-1 at 37°C for about 18 h. The non-
invaded cells were then removed using a cotton swab, and the invaded cells at the bottom 
of the insert were fixed with 100% methanol and stained with 0.2% Crystal Violet for 10 
min. The images were taken by EVOS xl microscope (20x) and the number of invaded cells 
counted in triplicate.   
2.2.8 siRNA Transfection in vitro 
          All transfection experiments were conducted in 48-well plates using cells at their 
logarithmic growth phase. B16F10-luc cells were seeded at a density of 8,000 cells/well 24 
h prior to transfection. Different formulations with 100 nM siRNA were prepared as 
mentioned above in 250 µL serum-free medium and then added onto cells. After 4 h 
incubation, the medium was removed and replaced with fresh culture medium. Cells 
were cultured for another 48 h before measuring luciferase expression. For harvesting 
cells, 100 µL of 0.5x cell culture lysis buffer (Promega, Madison, WI) was added to the 
cells after discarding the culture medium and then lysed for at least 20 min at room 
temperature. The cell lysate was then transferred to 1.5 mL tubes and all the samples were 
centrifuged at 10,000 g for 10 min at 4°C. To measure the luciferase expression, 100 µL of 
0.5 mM luciferin solution was automatically injected into each well containing 20 µL of 
cell lysate supernatant and the luminescence was integrated over 10 s using GloMax 96 
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Microplate Luminometer (Promega). Total cellular protein in the cell lysate was 
measured by the bicinchoninic acid protein assay using calibration curve constructed with 
standard bovine serum albumin solutions (Pierce, Rockford, IL). Transfection activity was 
expressed as % luciferase activity of siScr treated groups ± SD of triplicate samples. 
2.2.9 siRNA Transfection in vivo 
          All animal experiments were conducted in compliance with the guidelines of the 
Institutional Animal Care and Use Committee of the University of Nebraska Medical 
Center. Six-week-old female C57BL/6 albino mice were subcutaneously injected with one 
million B16F10-luc cells and randomized to different treatment groups to avoid cage 
effects. When a tumor reached a volume of 50 mm3, the mice (in groups of 7) were injected 
intravenously (i.v.) with different polyplexes or conjugate polyplexes at siRNA dose of 1 
mg/kg body weight daily for 4 days. Dextrose was added into each formulation to make 
a concentration of 5% before injection. The luminescence signal was detected in tumor 
before and after treatment using the Perkin Elmer IVIS bioluminescence imaging system. 
24 h after the last injection, all mice were sacrificed, and the tumors were harvested and 
homogenized in 1x Cell Culture Lysis Reagent (Promega, Madison, WI) followed by 
centrifugation at 10,000 g for 5 min. The luciferase expression was measured as described 
in 2.7. Transfection activity was expressed as % luciferase expression relative to scrambled 
siRNA (siScr) control groups ± SD. 
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2.2.10 Statistical Analysis 
          Data are presented as the means ± SD. The statistical significance of the mean values 
of all groups was determined by using one-way ANOVA. An unpaired t test was used to 
compare the means of two different groups. A P value < 0.05 was considered statistically 
significant. 
3. Results and Discussions 
3.1 Preparation of Albumin-coated Polyplexes and Conjugate Polyplexes  
          Conventional siRNA polyplexes are formed by electrostatic interactions between 
polycations and the nucleic acid. One of the major challenges of these polyplexes when 
applied in vivo is their stability against disassembly with competing polyelectrolytes and 
other charged molecules in serum. Several viable solutions have been developed, 
including covalent conjugation of siRNA to polymer carriers [237]. As part of our long-
term goal to develop CXCR4-inhibiting polycations (rPAMD) for siRNA delivery, we 
have adopted siRNA conjugation as a strategy to enable systemic administration of 
rPAMD/siRNA polyplexes. We proposed that assembling the hyperbranched 
bioreducible rPAMD with 5’-thiol functionalized siRNA will lead to facile in situ 
stabilization of the formed conjugate polyplexes by thiol-disulfide exchange reaction 
between siRNA-SH and the abundant disulfides in rPAMD (Scheme 3). We proposed that 
electrostatic interactions would dominate the initial formation of the polyplexes and that 
the thiol-disulfide exchange will then proceed rapidly within the formed polyplexes 
because of the local high concentration of the disulfides and thiols within the polyplexes 
(Scheme 3).  
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          We have prepared both conventional polyplexes (rPAMD/siRNA) and conjugate 
polyplexes (rPAMD-SS-siRNA) at two different polymer/siRNA w/w ratios (2 and 5). The 
formation of the conjugate polyplexes was confirmed by assessing stability against 
polyelectrolyte exchange with heparin (Figure 16a). While no free siRNA was observed at 
any samples in the absence of heparin, the presence of as little as 60 µg/mL heparin caused 
complete dissociation of the conventional polyplexes prepared at w/w 2 and in the 
presence of 100 µg/mL heparin in case of polyplexes prepared at w/w 5. In contrast, the 
conjugate polyplexes showed strong resistance to heparin-induced disassembly at both 
w/w ratios, with only a small amount of free siRNA released by the action of heparin. The 
heparin exchange assay distinguishes between electrostatically and covalently bound 
siRNA. The small amount of free siRNA released from the conjugate polyplexes suggested 
that not all siRNA-SH participated in the thiol-disulfide exchange, most likely because of 
partial siRNA-SH oxidation. It is worth noting that the thiol-disulfide exchange may lead 
to a degradation of rPAMD. The extent of the disulfide cleavage, however, depends on 
the ratio of the siRNA-SH thiols to rPAMD disulfides present in the formulation. For 
example, formulations prepared at w/w ratio of 5 contain ~89 disulfides for each siRNA-
SH. We assumed that the molecular weight of siRNA-SH is about 13 600 g/mol and that 
the molecular weight of the repeating unit per 1 disulfide in rPAMD is 764 g/mol. For a 
typical rPAMD/siRNA-SH formulation prepared at w/w ratio of 5, that translates to about 
89 disulfides per each thiol (5/764)/(1/13 600). In such a case, the extent of rPAMD cleavage 
is negligible since only about 1% of the disulfides can be cleaved by the HS-siRNA.  
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          Successful use of any polyplex stabilization strategy requires that the stabilization 
is reversible, and that siRNA is released in the cytoplasm. We have incubated the 
polyplexes with 10 mM DTT to simulate intracellular reducing environment and to 
confirm reversibility of the conjugate polyplexes. As shown in Figure 16a, disulfide 
reduction with DTT destabilized both the polyplexes and conjugate polyplexes and 
resulted in a complete release of siRNA. No differences were observed between 
polyplexes prepared at the different w/w ratios. 
          The effect of physiological salt concentration on the integrity of the polyplexes was 
investigated by incubation in PBS. High salt concentrations can weaken the electrostatic 
interactions between siRNA and polycation and cause polyplex disassembly. The 
destabilizing effect of PBS was clearly demonstrated in rPAMD/siRNA polyplexes by the 
significant amount of released siRNA over the 24 h incubation period (Figure 16b). 
Polyplexes prepared at w/w 5 were more resistant to salt dissociation than those prepared 
at w/w 2. As above, the conjugate polyplexes displayed greatly enhanced stability in 
physiological saline as documented by no significant siRNA release. Combination of high 
ionic strength with the complex mix of proteins and other charged molecules found in 
serum can further destabilize the polyplexes and so the stability was further tested in 50% 
serum (FBS) (Figure 16b). As expected, conventional polyplexes disassembled rapidly in 
the presence of serum and significant amount of the siRNA was degraded within 24 h as 
suggested by the fading band of the free siRNA in the gel. Conjugate polyplexes showed 
high stability against disassembly, although the appearance of fluorescence in the start 
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well of the conjugate polyplexes at w/w 2 suggested that serum at least partially 
disrupted the polyplexes structure and allowed binding of ethidium bromide to siRNA.  
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Scheme 3. Preparation of HSA[rPAMD-SS-siRNA] conjugate polyplexes 
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Figure 16. Stability of polyplexes and conjugate polyplexes against disassembly. (a) 
Heparin-induced siRNA release from the polyplexes and conjugate polyplexes prepared 
at w/w ratio = 2 and 5 in 5 mM HEPES buffer (pH 7.4) and incubated with increasing 
concentrations of heparin with (+) or without (-) 20 mM DTT. (b) Stability of the polyplexes 
and conjugate polyplexes in 50% FBS and PBS following incubation for 0-24 h. The release 
of free siRNA in both (a) and (b) was visualized by agarose gel electrophoresis. (c) Free 
siRNA degradation profile in 50% FBS. 
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3.2 Colloidal Characterization  
          Hydrodynamic size and zeta potential are important parameters that determine the 
cellular uptake, pharmacokinetics and biodistribution of polyplexes. We have measured 
the size and ζ potential of polyplexes and conjugate polyplexes prepared in 5 mM HEPES 
(pH 7.4) at both w/w ratios by dynamic light scattering (Figure 16 and 17). Polyplexes and 
conjugate polyplexes with both tested w/w ratios showed similar sizes in a range from 
120-160 nm (Figure 16a) and positive ζ potentials ranging from 15 to 22 mV (Figure 17). 
The size of the conjugate polyplexes was slightly larger than the sizes of the conventional 
polyplexes. We have then assessed colloidal stability of both formulations by measuring 
the changes in size following a 4 h incubation in PBS (Figure 16b). As expected, the 
rPAMD/siRNA polyplexes showed poor colloidal stability indicated by rapid aggregation 
with sizes reaching nearly 800 nm within 4 h. In contrast, the conjugate polyplexes 
remained relatively stable even in PBS as their sizes increased only to 210-246 nm. When 
combined with the data in Figure 16b, the improvement in colloidal stability may suggest 
intra-particle crosslinking of the conjugate polyplexes by the catalytic action of the free 
thiols in siRNA-SH, similar to previously reported increase in colloidal stability of 
crosslinked DNA polyplexes [255]. 
3.3 Effect of albumin coating on polyplex properties 
          Both polyplex and conjugate polyplex showed highly positive surface charge, which 
made them ill-suited for in vivo use. Covalent conjugation of poly(ethylene glycol) (PEG) 
is the most common method to shield the positive surface charge of polyplexes. Here, we 
explored alternative approach to shielding the positive surface charge by adsorption of 
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HSA. Polyplexes and conjugate polyplexes were prepared as described above and then, 
HSA was added and allowed to adsorb to the surface of the polyplexes (Scheme 3). We 
first confirmed that HSA has no effect on polyplex stability against disassembly with 
heparin, serum, or PBS (Figure 16). The polyplexes coated with HSA showed slightly 
smaller hydrodynamic size in 10 mM HEPES (pH 7.4) (Figure 17a) but no effect of HSA 
on colloidal stability in PBS was observed (Figure 17b). Importantly, adsorption of the 
negatively charged HSA significantly decreased the ζ potential of both polyplexes and 
conjugate polyplexes in solution with pH 7.4 (Figure 18), thus making them better suited 
for the subsequent in vivo testing.  
          The HSA coating is strongly dependent on pH and because of the isoelectric point 
of albumin (4.9), we predicted that the coating would be reversed during endo/lysosomal 
trafficking of the polyplexes. We have thus prepared the coated polyplexes at pH 7.4 and 
then decreased the pH to 5 and observed the effect of the pH change on particle size 
(Figure 16c) and ζ potential (Figure 18). While the pH change had no significant effect of 
the particle size, we have observed significant increase in the ζ potential for both 
polyplexes and conjugate polyplexes. The ζ potential increased to the levels comparable 
to those found for the non-coated polyplexes, thus strongly suggesting that HSA 
dissociated from the polyplexes. Such behavior may be beneficial for the intracellular 
trafficking of the polyplexes as it may lead to exposure of unmodified rPAMD/siRNA in 
the endo/lysosomes and ultimately improve cytoplasmic transport. 
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Figure 17. Hydrodynamic size. Polyplexes and conjugate polyplexes were prepared at 
w/w ratio = 2 and 5 in 5 mM HEPES buffer (pH 7.4) and coated with HSA. Hydrodynamic 
size was measured by dynamic light scattering. (a) Hydrodynamic size in 5 mM HEPES 
buffer (pH 7.4); (b) Hydrodynamic size after 4 h incubation in PBS, and (c) Hydrodynamic 
size after adjustment of pH from 7.4 to 5. All data shown as mean ± SD (n = 3). 
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Figure 18. Zeta potential. Polyplexes and conjugate polyplexes were prepared at w/w 
ratio (a) 2 and (b) 5 in 5 mM HEPES buffer (pH 7.4), coated with HSA, and pH was 
adjusted to 5. All data shown as mean ± SD (n = 3). 
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3.4 Cytotoxicity and Transfection Activity in vitro 
          Another important consideration for systemic siRNA delivery is to minimize 
toxicity of the polyplexes. The use of bioreducible polycations such as rPAMD 
substantially decreases cytotoxicity when compared with non-reducible polycations [256-
258]. To ensure that the formation of conjugate polyplexes and HSA coating had no 
reverse effects on cytotoxicity, we evaluated the effect of polyplexes and conjugate 
polyplexes on cell viability of a mouse melanoma B16F10-luc cell line (Figure 19). We have 
determined cell viability at three different rPAMD concentrations: 2, 8 and 15 µg/mL and 
found no significant adverse effect with any of the formulations as the cell viability 
remained above 90%.  
          The ability of the polyplexes and conjugate polyplexes to silence expression of the 
luciferase reporter gene was studied in B16F10-luc cells (Figure 20). 
Oligofectamine/siRNA complexes were used as a control in all luciferase silencing studies. 
Treatment with formulations prepared with negative control (siScr) showed no effect on 
luciferase expression, confirming safety of the studied systems. Overall, the conjugate 
polyplexes rPAMD-SS-siRNA exhibited better luciferase silencing activity than 
rPAMD/siRNA polyplexes at both w/w ratios. As expected polyplexes prepared at w/w 5 
showed better silencing activity than those at w/w 2. HSA coating had a small, but 
significant, positive effect on the silencing activity of the conjugate polyplexes but no 
effect on the activity of the conventional polyplexes. We found that HSA[rPAMD-SS-
siRNA] prepared at w/w 5 showed the best luciferase silencing as they decreased the 
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expression to ~45%. The best performing conjugate polyplexes showed activity fully 
comparable to the Oligofectamine control.   
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Figure 19. Cytotoxicity of polyplexes and conjugate polyplexes in B16F10-luc. Cells were 
treated with the formulations prepared at (a) w/w 2 and (b) w/w 5. Data are shown as 
mean viability ± SD (n = 3).  
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Figure 20. Transfection activity of polyplexes and conjugate polyplexes. Formulations 
were prepared either with siLuc or control siScr at (a) w/w ratio 2 or (b) w/w ratio 5. 
Luciferase silencing was determined by in B16F10-luc cells. Data are shown as mean % 
luciferase expression ± SD (n = 3). * p < 0.05, ** p < 0.01, *** p < 0.001. 
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3.5 CXCR4 Antagonism and Inhibition of Cancer Cell Invasion 
          We have developed rPAMD as antimetastatic inhibitors of the chemokine receptor 
CXCR4 and it was important to validate that the conjugate polyplexes retained the 
original CXCR4 inhibitory activity. First, we measured CXCR4 inhibition using CXCR4 
redistribution assay by a high-content fluorescence microscopy analysis as described 
previously [259, 260]. We have used a small molecule CXCR4 inhibitor AMD3100 as a 
positive control and expressed the results as % of the AMD3100 activity. As shown in 
Figure 21a, we have found that all tested formulations used at concentrations used in the 
siRNA silencing studies showed CXCR4 inhibition indistinguishable from the activity of 
300 nM AMD3100. We then investigated if the demonstrated CXCR4 inhibition resulted 
in the ability of the polyplexes and conjugate polyplexes to inhibit invasion of cancer cells. 
The important role of CXCR4 in the migration and invasion of multiple types of cancer 
cells and the ability of CXCR4 inhibitors to prevent the migration is well known [261]. We 
have previously shown that both rPAMD and rPAMD/DNA polyplexes effectively inhibit 
CXCR4-mediated invasion of multiple cancer cells [254, 262]. As shown in Figure 21b, all 
the polyplexes and conjugate polyplexes showed effective inhibition of cell invasion at 
w/w ratio either 2 or 5. Based on the quantification of the average numbers of invaded 
cells, 71% cancer cells were prevented from invading and migrating through the layer of 
Matrigel by control AMD3100. The polyplexes and conjugate polyplexes achieved similar 
activity as they inhibited invasion of 60-70% cancer cells. Both of the above experiments 
together demonstrated that the conjugate polyplexes retain the CXCR4 activity of rPAMD. 
While the mechanism of the CXCR4 inhibition by the conjugate polyplexes is not fully 
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understood, we believe that excess rPAMD used in the formulations is most likely 
responsible for the observed activity. Additional CXCR4 inhibition is likely contributed 
as rPAMD is released and degraded in the cells following intracellular delivery and 
disassembly of the conjugate polyplexes. 
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Figure 21. Inhibition of CXCR4 and cancer cell invasion. (a) CXCR4 inhibition of 
polyplexes and conjugate polyplexes in U2OS cells. AMD3100 (300nM) was used as a 
positive control. Data are shown as mean % CXCR4 antagonism relative to AMD3100 ± 
SD (n = 3). (b) Inhibition of cancer cell invasion. U2OS cells were treated with polyplexes 
or conjugate polyplexes (rPAMD 2.0 µg/mL) and allowed to invade through Matrigel 
upon stimulation with SDF-1 for 16 h. AMD3100 (300 nM) was used as positive control. 
Data are shown as mean number of invaded cells ± SD (n = 3).  
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3.6 Transfection Activity in vivo  
          The ability of the conjugate polyplexes to deliver siRNA systemically after 
intravenous injection was investigated in mice bearing B16F10-luc tumors. We first 
conducted a dose-finding and preliminary toxicity evaluation of both conventional 
polyplexes and conjugate polyplexes both with and without HSA coating. We found that 
coating with HSA improves safety of both formulations and increases the estimated 
maximum tolerated dose about 2.5-fold (not shown). We thus focused our attention on 
the HSA-coated formulations. The B16F10-luc cells were injected subcutaneously and the 
tumor growth was followed by IVIS bioluminescence imaging. We have started the 
treatments with HSA[rPAMD-SS-siRNA] and HSA[rPAMD/siRNA] when the tumors 
reached 50 mm3. Both conjugate polyplexes and conventional polyplexes were prepared 
with siLuc and siScr. The control siScr formulations were injected to establish 100% 
luciferase expression levels. Following the treatments and shortly before animal sacrifice, 
whole-body luminescence images were taken (Figure 22a) and luciferase expression in the 
tumor regions quantified. As shown in Figure 22b, the HSA-coated conjugate polyplexes 
showed increased luciferase silencing (~50%) when compared with the HSA-coated 
conventional polyplexes (~30%). The tumors were resected, mechanically homogenized, 
lysed and the luciferase silencing was validated in the tumor lysates as above (Figure 22c). 
The tumor lysate results confirmed the superior silencing activity of the conjugate 
polyplexes. The observed improved in vivo activity of the conjugate complexes confirmed 
the in vitro findings and showed the importance of the polyplex stabilization for systemic 
delivery. The primary benefit of coating with albumin appeared to be decrease in systemic 
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toxicity most likely due to reduction in the surface charge. Potential effects of the HSA 
coating on pharmacokinetics and renal clearance remain to be investigated.  
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Figure 22. In vivo luciferase gene silencing by HSA-coated conjugate polyplexes. Mice 
with subcutaneous B16F10-luc tumors were given daily intravenous injections for 4 days 
of the HSA-coated polyplexes or conjugate polyplexes prepared with either siLuc or 
control siScr. (a) Bioluminescence images of the tumor-bearing mice before sacrifice. (b) 
Luciferase silencing determined from the region of interest analysis of the tumor-
associated signal in live animals. Luciferase expression in animals treated with siScr was 
set as 100%. (c) Luciferase silencing in homogenized tumor tissues. Data are expressed as 
mean ± SEM (n = 7). * p < 0.05, ** p < 0.01. 
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4. Conclusions 
          In conclusion, we described a simple approach to prepare polyplexes stabilized 
against dissociation using in situ thiol-disulfide exchange between siRNA-SH and 
bioreducible branched polycations. Our results demonstrated not only increased overall 
stability of the conjugate polyplexes but also enhanced gene silencing activity in vitro and 
in vivo. Further stabilization of the polyplexes by surface coating with albumin provided 
additional enhancement of gene silencing in vitro and decrease of toxicity in vivo. Using 
polycations that inhibit CXCR4, we confirmed that even when conjugated to the siRNA, 
these polycations retain their inhibitory activity as suggested by strong ability to prevent 
invasion of cancer cells. Overall, these initial findings provide impetus for further 
evaluation of the conjugate polyplexes in systemic anticancer and antimetastatic siRNA 
therapies. In the future, these innovative conjugate polyplexes can also be evaluated in 
systemic renoprotection of AKI. 
Note: Reprinted (adapted) with permission from [263]. Copyright (2018) American 
Chemical Society. 
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Chapter 5. Summary and Future Directions 
          AKI has high mortality and morbidity and remains the significant medical problem 
in the world. It affects over 13 million patients worldwide every year. People who has AKI 
may finally have chronic kidney disease or even ultimately kidney failure. However, there 
are few effective pharmaceutical treatments to prevent AKI due to its complex 
pathogenesis. It may be necessary to develop dual- or multi- functional methods to 
simultaneously treat AKI. In recent years, drug targeting to the proximal tubule cells, 
which are the primary injured site in AKI could provide better treatment by means of 
enhancing the therapeutic efficacy of drugs and lowering unwanted side effects in other 
organs. Thus, we first developed a variety of polymers with different physicochemical 
properties for better understanding how those properties influence the distribution in 
kidney with AKI. After we successfully synthesized pAPMA, pMAA and pHPMA with 
different sizes, we found that the negatively charged pMAA-5 and neutral polymer of 
pHPMA-36 showed increased accumulation in injured kidneys at 24 hours after 
administration. These results confirmed that different properties of polymers have an 
effect on their deposition in kidneys.  
          Cytokines and chemokines are elevated in response to AKI, leading to a 
proinflammatory microenvironment. Emerging evidence shows that the CXCR4/SDF-1 
axis is implicated in regulating trafficking and invasion of inflammatory cells in the 
injured kidneys and inhibition of the axis exerts beneficial therapeutic effect in 
experimental AKI animal models. siRNA has been used to successfully ameliorate AKI by 
inhibiting specific gene expression through hydrodynamic injection. However, the 
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hydrodynamic injection produces high pressure during administration which will lead 
to liver damage and local renal dysfunction. Therefore, we developed a novel combination 
therapeutic strategy for systemic treatment of AKI based on previously synthesized dual-
function polymeric CXCR4 inhibitors (PCX) capable of systemically delivering siRNA 
targeting GAPDH (siGAPDH) to the kidneys with AKI. By using this polymer, we safely 
and efficiently delivered siRNAs to kidneys. First, we confirmed the increase in CXCR4 
level of kidney after I/R surgery. Then we demonstrated that our polymer and polyplexes 
have the potential to accumulate in kidneys with cisplatin-induced AKI. For therapeutic 
effect, our anti-CXCR4 polymer demonstrated renoprotective effect on cisplatin induced 
AKI animals by means of inhibision of CXCR4. In addition, the polyplexes showed 
increased siRNA silencing efficiency when compared with hydrodynamic injection. By 
doing so, we successfully ameliorate AKI not only by siRNA silencing, but also through 
interference of the CXCR4/SDF-1 signaling pathway. This method will be a promising 
therapeutic way for the treatment of AKI.  
          Conventional siRNA polyplexes are formed by electrostatic interactions between 
polycations and the nucleic acid. The cationic carriers may not form sufficiently strong 
interactions with anionic siRNA simply through electrostatic interactions because of the 
relatively small size of siRNA. Therefore, one of the major challenges of these polyplexes 
when applied in vivo is their stability against disassembly with competing polyelectrolytes 
and other charged molecules in serum. To overcome the limitations of siRNA in effective 
electrostatic condensation with polycations, we tested a simple thiol-disulfide exchange 
conjugation strategy to prepare rPAMD-SS-siRNA polyplex conjugates and their stability 
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in serum and against heparin exchange significantly increased. Reporter gene silencing 
activity of the polyplex conjugates in B16F10-luc mouse melanoma cells showed a 
comparable efficiency with commercialized Oligofectamine. Finally, the systemic siRNA 
delivery efficacy of the developed polyplex conjugates in vivo in a syngeneic tumor model 
showed a promising silencing effect. 
          Our future studies will focus on drug delivery using the selected polymers that 
specifically target kidneys with AKI. On the other hand, we will also improve the polyplex 
formulations and on the renoprotective effect of these polyplexes in AKI. The 
pathophysiological roles of the novel pharmacological dual-functional polyplexes will be 
evaluated in several proteins overexpressed during AKI. Last but not the least, we will 
improve survival rate of mice with AKI. 
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